

# A framework for perioperative care for lower extremity vascular bypasses: a Consensus Statement by the Enhanced Recovery after Surgery (ERAS®) Society and Society for Vascular Surgery

Katharine L. McGinagle, MD, MPH,<sup>a</sup> Emily L. Spangler, MD, MS,<sup>b</sup> Katie Ayyash, MBChB, BSc, FRCA, MSc,<sup>c</sup> Shipra Arya, MD, MS,<sup>d</sup> Alberto M. Settembrini, MD,<sup>e</sup> Merin M. Thomas, PA-C,<sup>f</sup> Kate E. Dell, DNP, AGACNP-BC,<sup>g</sup> Iris J. Swiderski, DHSc, MPAS, PA-C,<sup>h</sup> Mark G. Davies, MD, PhD, MBA,<sup>i</sup> Carlo Setacci, MD,<sup>j</sup> Richard D. Urman, MD, MBA,<sup>k</sup> Simon J. Howell, MA, MRCP, FRCA, MSc, MD,<sup>l</sup> Joy Garg, MD,<sup>m</sup> Olle Ljungqvist, MD, PhD,<sup>n</sup> and Hans D. de Boer, MD, PhD, BC,<sup>o</sup> Chapel Hill, NC; Birmingham, AL; Palo Alto, and San Leandro, CA; New Hyde Park, NY; Lafayette, IN; Melbourne, FL; San Antonio, TX; Boston, MA; York, and Leeds, United Kingdom; Milan, and Siena, Italy; Orebro, Sweden; and Groningen, the Netherlands

## ABSTRACT

The Society for Vascular Surgery and the Enhanced Recovery After Surgery (ERAS) Society formally collaborated and elected an international, multi-disciplinary panel of experts to review the literature and provide evidence-based suggestions for coordinated perioperative care for patients undergoing infrainguinal bypass surgery for peripheral artery disease. Structured around the ERAS core elements, 26 suggestions were made and organized into preadmission, preoperative, intraoperative, and postoperative sections. (J Vasc Surg 2023;■:1-21.)

**Keywords:** Analgesia and anesthesia; Enhanced recovery after surgery; Evidence-based recommendations; Guidelines; Infrainguinal bypass surgery; Perioperative care; Peripheral artery disease

## TABLE OF CONTENTS

<b>METHODS</b> .....	2
Formation of the Guideline Development Group and selection of topics .....	2
Literature search strategy .....	2
Quality assessment, data analyses, and consensus generation .....	3

<b>RESULTS</b> .....	3
<b>PREADMISSION RECOMMENDATIONS</b> .....	3
1. Patient information, education, and counseling .....	3
2. Assessment and optimization: (a) nutritional deficiency; (b) anemia screening; (c) frailty; (d) delirium risk; (e) psychosocial concerns, and (f) tobacco and alcohol overconsumption .....	3

From the Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill<sup>a</sup>; the Department of Surgery, School of Medicine, University of Alabama at Birmingham, Birmingham<sup>b</sup>; the Department of Perioperative Medicine (Merit), York and Scarborough Teaching Hospitals NHS Foundation Trust, York<sup>c</sup>; the Department of Surgery, School of Medicine, Stanford University, Palo Alto<sup>d</sup>; the Fondazione IRCCS Ca' Granda Policlinico, Milan<sup>e</sup>; the Lenox Hill Hospital, Northwell Health, New Hyde Park<sup>f</sup>; the Ascension Medical Group, Lafayette<sup>g</sup>; the Medical Associates of Brevard, Melbourne<sup>h</sup>; the Department of Surgery, Joe R. & Teresa Lozano Long School of Medicine, University of Texas Health Sciences Center, San Antonio<sup>i</sup>; the Department of Surgery, University of Siena, Siena<sup>j</sup>; the Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston<sup>k</sup>; the Leeds Institute of Medical Research at St James's, University of Leeds, Leeds<sup>l</sup>; the Department of Vascular Surgery, Kaiser Permanente San Leandro, San Leandro<sup>m</sup>; the Department of Surgery, Orebro University, Orebro<sup>n</sup>; and the Department of Anesthesiology, Pain Medicine, and Procedure Sedation and Analgesia, Martini General Hospital Groningen, Groningen.<sup>o</sup>

Author conflict of interest: H.d.B. reports Chairman of ERAS Society; global advisory board of Merck & Co, Inc; scientific advisory board of Senzime; global advisory board of NMD Pharma; and recipient of research grants from Merck & Co, Inc, and The Medicines Company; O.L. reports co-founder and past Chairs of

ERAS Society; founder and shareholder of ENcare AB (SE); advisor to Nutricia (NL); honorarium recipient of Nutricia (NL), Fresenius-Kabi (DE), Pharmacosmos (DK) and Medtronic (IT); R.D.U. reports fees and/or funding from Pfizer, Merck, Covidien, Acel Rx, Heron, Cook; federal funding from the National Institutes of Health, National Science Foundation; Vice-President ERAS USA.

Independent peer review and oversight has been provided by the members of the Society for Vascular Surgery Document Oversight Committee (Marc Schermerhorn, Chair, Britt Tonnessen, Vice Chair, Mohammad Eslami, Raul Guzman, Peter Henke, Vikram Kashyap, Ahmed Kayssi, Chris Kwolek, Erika Mitchell, Patrick Muck, William Robinson, Evan Ryer, Palma Shaw, Chris Smollock, Chandu Vemuri, Greg Westin, and Karen Woo).

Correspondence: Katharine L. McGinagle, MD, MPH, Department of Surgery, School of Medicine, University of North Carolina at Chapel Hill, 3022 Burnett-Womack Bldg, CB 7212, Chapel Hill, NC 27599 (e-mail: [Katharine\\_mcginagle@med.unc.edu](mailto:Katharine_mcginagle@med.unc.edu)).

The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

0741-5214

Copyright © 2023 by the Society for Vascular Surgery. Published by Elsevier Inc.

<https://doi.org/10.1016/j.jvs.2023.01.018>

2a. Nutritional deficiency .....	3
Anemia screening .....	3
Frailty .....	5
Delirium risk .....	6
Psychosocial concerns .....	6
Tobacco and alcohol cessation .....	6
Medical risk .....	7
Cardiac risk .....	7
Pulmonary risk .....	7
Glycemic control .....	7
Perioperative antithrombotic strategy/plan .....	8
Resuming antiplatelet and anticoagulation medications .....	8
<b>PREOPERATIVE RECOMMENDATIONS</b> .....	9
4. Fasting .....	9
Carbohydrate loading .....	9
Venous thromboembolism prophylaxis .....	10
7. Pre-anesthetic sedative and analgesia medication .....	10
8. Antimicrobial prophylaxis and skin preparation to reduce surgical site infections ....	10
9. Prevention of nausea and vomiting .....	11
<b>INTRAOPERATIVE RECOMMENDATIONS</b> .....	11
10. Anesthetic protocol .....	11
11. Goal-directed fluid therapy .....	11
12. Body temperature management .....	12
13. Surgical access and techniques .....	12
Autologous blood salvage .....	12
Groin incisions and closure .....	12
Vein harvest .....	12
Hybrid surgery .....	13
<b>POSTOPERATIVE RECOMMENDATIONS</b> .....	13
14. Multimodal analgesia and opioid reduction .....	13
15. Oral feeding .....	13
16. Glycemic control .....	13
17. Urinary drainage .....	14
18. Early mobilization .....	14
19. Discharge criteria and post discharge education .....	14
<b>SUMMARY AND CONCLUSION</b> .....	14
<b>AUTHOR CONTRIBUTIONS</b> .....	15

Enhanced Recovery After Surgery (ERAS) pathways have been beneficial for many surgical specialties, and have recently been developed for open aortic surgery.<sup>1,2</sup> The concept of multi-disciplinary care to control perioperative physiology and maintain hemostasis to attenuate stress and accelerate convalescence was first described in 1997.<sup>3</sup> Since then ERAS has spread to six continents, and 20 surgical specialties have published formal ERAS Society consensus statements. Although each specialty and geographic region may be unique, the common foundational theme is to create a culture in which all perioperative physicians, surgeons, nurses, and therapists work together within a clinical pathway to apply evidence-based practice in unison.

Vascular surgery patients, specifically patients with peripheral artery disease (PAD), present unique challenges due to their advanced age, frailty, and multiple comorbidities compared with the general population. This combination of factors results in complex management strategies, increased utilization of health care resources, prolonged hospitalizations, and rehabilitation needs.<sup>4</sup> ERAS, with its aim of delivering high-quality perioperative care and accelerating recovery, appears well-suited to address the needs of patients undergoing infrainguinal bypass operations, but unfortunately, there is not enough published data to support formal ERAS guidelines. To reduce unwarranted clinical practice variation and to potentially enhance clinical care, this document is a synthesis of the existing literature for best practices and provides a framework for the perioperative care of patients undergoing open surgical infrainguinal bypass. The paper also shows the gaps in the literature and suggests areas where research is needed for more robust knowledge to improve the care for this patient group.

## METHODS

**Formation of the Guideline Development Group and selection of topics.** In collaboration, the Society for Vascular Surgery and the ERAS Society initiated the formation of the multidisciplinary, international Guideline Development Group (GDG), which consisted of vascular surgeons, anesthesiologists, and advanced practice providers with expertise in ERAS and vascular pathophysiology. The GDG was consulted for advice on appropriate items to be included, with the final decision being made by the lead authors (KM and HDB). The selected topics for the consensus statement were allocated to authors for literature summary depending on each individual's expertise. The final content was agreed upon by all authors.

**Literature search strategy.** A third-party team of investigators and a reference librarian specializing in literature reviews assisted the GDG in identifying and categorizing the existing effectiveness and comparative effectiveness literature on ERAS protocols relevant to vascular surgery. The librarian executed and documented the search in July 2019 (Appendix 1). The databases queried included PubMed, CINAHL, and [clinicaltrials.gov](https://clinicaltrials.gov). Systematic reviews, randomized controlled trials (RCTs), and observational cohort studies reporting on adults ( $\geq 18$  years) undergoing lower extremity vascular surgery and reporting on any one or combinations of the ERAS guideline items were included. GDG members then searched reference lists and repeated literature searches to include any new publications through December 2021. Many ERAS items had not been studied specifically in patients undergoing

infrainguinal bypass, so published data and ERAS guidelines from other surgical specialties were included for the elements that were generalizable. The included studies were carefully reviewed by the GDG, who unanimously agreed upon them.

**Quality assessment, data analyses, and consensus generation.** Suggestions for best perioperative practices were made based on the supporting literature specific to this patient population, and, at times, supporting literature extrapolated from other surgical populations. Assessment of the quality of evidence was judged to be high, moderate, or low. Where non-vascular literature was used as a primary basis for suggestions, the quality of evidence was extrapolated to this population and indicated in each section. Because of this, although some of the practice suggestions are based from a high-quality evidence base and are unlikely to change, other suggestions are merely from expert consensus or low-quality evidence and may change if more rigorous research is performed.

The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system was used to judge the literature, but formal recommendations using the GRADE system were not made across all elements due to lack of consistently high-quality data derived from this specific patient population.<sup>5</sup>

## RESULTS

The literature search yielded 3460 citations. There were 109 studies addressing ERAS interventions, as either individual core elements or combinations of elements, in vascular surgery patients, and another 18 studies included mixed cohorts, including vascular surgery patients. Most of these studies involved vascular patients with abdominal aortic pathology, and only 45 involved patients undergoing lower extremity vascular operations. Structured around the 22 ERAS core elements, 26 suggestions for best perioperative practices were made and organized into preadmission, preoperative, intraoperative, and postoperative sections (Table).

## PREADMISSION RECOMMENDATIONS

### 1. Patient information, education, and counseling

Preoperative education and counseling are cornerstones of ERAS pathways to engage patients and caregivers in all aspects of their perioperative care. It allows setting and managing expectations regarding early mobility, postoperative pain control, anticipated length of stay (LOS), and follow-up.<sup>6,7</sup> Although studies on lower extremity bypass-specific education strategies are lacking, there is literature, including an RCT, from other general surgical specialties on use of extended pre- and postoperative counseling, guidance by an ERAS nurse, and written information leads to less pain, less nausea,

reduced time as an inpatient, and increased enhanced recovery pathway adherence.<sup>8-10</sup>

*Suggestion:* Patients should receive dedicated verbal and written preoperative education and counseling.

*Quality of evidence:* Low.

### 2. Assessment and optimization: (a) nutritional deficiency; (b) anemia screening; (c) frailty; (d) delirium risk; (e) psychosocial concerns, and (f) tobacco and alcohol overconsumption

**2a. Nutritional deficiency.** Poor nutrition in patients with PAD undergoing revascularization correlates with worse outcomes, including increased mortality and risk of major amputation.<sup>11-14</sup> Poor nutrition also significantly impacts wound healing in patients with chronic limb-threatening ischemia, a group that is particularly high-risk for baseline malnutrition.<sup>13,15,16</sup> Coupled to these issues, limited mobility due to rest pain, tissue loss, or prior contralateral amputation can induce a decline in basal energy expenditure, reduced insulin sensitivity, anabolic resistance to protein nutrition, and muscle strength.<sup>17</sup>

Preoperative nutritional deficiency can be established by screening.<sup>18</sup> There are many nutritional screening tools available, and only expert consensus regarding the best; however, the European Society for Clinical Nutrition and Metabolism (ESPEN) suggests the Malnutrition Universal Screening Tool (MUST) be used in the outpatient community setting, and Nutritional Risk Screening 2002 (NRS 2002) for inpatients.<sup>18,19</sup> These guidelines have suggested specific parameters for severe nutritional risk based on weight loss, body mass index, and preoperative serum albumin concentration.

If one of these criteria is present, formal nutritional assessment is needed, and targeted nutritional therapy should be initiated.<sup>18,19</sup> Oral nutritional supplements, including those containing immunonutrients,<sup>20-22</sup> are almost always preferred to enteral or parenteral nutrition regimens.<sup>18</sup> Regimens for treating malnutrition via oral nutritional supplementation have shown greatest effect if started at least 7 to 10 days preoperatively in non-vascular cohorts.<sup>23-26</sup>

*Suggestion:* Screen for malnutrition and treat nutritional deficiency preferably with oral regimens.

*Quality of evidence:* Moderate.

**2b. Anemia screening.** Preoperative anemia, is associated with poor outcomes after surgery and is common in patients undergoing lower extremity arterial bypass.<sup>27-30</sup> Although blood transfusion can quickly correct preoperative anemia, caution should be used, as transfusion is also associated with increased mortality and morbidity.<sup>31,32</sup> There are benefits to avoiding transfusion, and it is recommended that patients who are at risk for transfusion such as those with severe anemia or with moderate to large volume blood loss (>500 mL) undergo testing and treatment for anemia when possible.<sup>33</sup>

**Table.** Best practice suggestion and level of evidence for each Enhanced Recovery After Surgery (ERAS) element

ERAS element	Suggestion	Evidence level
<b>Preadmission</b>		
1. Patient information, education, counseling	Patients should receive dedicated verbal and written preoperative education and counseling.	Low <sup>a</sup>
2a. Screening, assessment, and optimization: nutritional deficiency	Screen for malnutrition and treat nutritional deficiency preferably with oral regimens.	Moderate <sup>a</sup>
2b. Screening, assessment, and optimization: anemia	Evaluate the cause of and treat chronic preoperative anemia.	Low
2c. Screening, assessment, and optimization: frailty	Screen for frailty as a routine part of preoperative patient assessment.	Moderate
2d. Screening, assessment, and optimization: delirium	Screen for delirium risk and implement preoperative practices to minimize onset of delirium as a routine part of practice.	Low
2e. Screening, assessment, and optimization: psycho-social	Routinely screen for depression.	Low
2f. Screening, assessment, and optimization: tobacco and alcohol	i. Prescribe smoking cessation therapy before surgery. ii. Recommend alcohol cessation prior to surgery.	High <sup>a</sup> Low <sup>a</sup>
2h. Screening, assessment, and optimization: medical risk	Evaluate and optimize comorbidities prior to elective surgery and consider medical risks before urgent surgery.	High
2i. Screening, assessment, and optimization: glycemic control	All patients should have a baseline HbA <sub>1c</sub> level prior to revascularization. In patients with elevated HbA <sub>1c</sub> levels, anti-hyperglycemic treatment should be initiated and/or titrated with the assistance of a specialist.	High
3. Preoperative anti-platelet, anticoagulation plan	Continue aspirin throughout the perioperative period.	High
<b>Preoperative</b>		
4. Fasting	Avoid overnight fasting; encourage clear fluids up to 2 hours and light foods up to 6 hours prior to the induction of general anesthesia.	High <sup>a</sup>
5. Carbohydrate loading	Patients without diabetes should receive a preoperative carbohydrate drink. Patients with stable diabetes should receive a preoperative carbohydrate drink alongside their anti-diabetic medication.	High <sup>a</sup> Low <sup>a</sup>
6. Venous thromboembolism prophylaxis	Routinely use either low-dose unfractionated heparin or low molecular weight heparin with calf-length intermittent compression devices, when possible, starting prior to surgery or within 24 hours of surgery end, and continuing throughout the hospitalization.	High <sup>a</sup>
7. Pre-anesthetic sedative and analgesia medication	i. Do not routinely use sedatives to reduce anxiety preoperatively. ii. Routinely use preoperative administration of acetaminophen, NSAIDs, and gabapentinoids as part of a multimodal opioid-sparing analgesia strategy. iii. For opioid-dependent patients, maintain outpatient pain regimen in the perioperative period.	Low <sup>a</sup> Low <sup>a</sup> Moderate <sup>a</sup>
8. Antimicrobials	i. Consider the use of bundles programs to reduce SSI. ii. Prophylactic IV antibiotic dosing should begin 30 to 60 minutes preoperatively with re-dosing intraoperatively for procedures greater than 4 hours or with substantive intraoperative blood loss and extend no more than 24 hours postoperatively.	Low High
9. PONV	Risk-assess for PONV, routinely use multimodal PONV prophylaxis based on assessment, and use PONV rescue with a different class of anti-emetic.	High <sup>a</sup>

**Table.** Continued.

ERAS element	Suggestion	Evidence level
<b>Intraoperative</b>		
10. Anesthetic protocol	Use a multimodal analgesic strategy which includes non-opioid analgesics and regional anesthesia.	Moderate
11. Goal directed fluid therapy	Routinely use cardiac monitoring (arterial line and non-invasive cardiac output monitoring such as stroke volume variation) to support euvolemia.	Low <sup>a</sup>
12. Body temperature management	Use multiple strategies to maintain normothermia, including pre-warming and active warming of patients intraoperatively.	Moderate <sup>a</sup>
13. Surgical techniques (vein harvest, groin closure)	i. Close groin incisions with subcuticular sutures and use a negative-pressure dressing.	Low
	ii. Harvest vein conduits with either continuous or skip open incisions rather than endoscopic harvest.	Low
	iii. Consider hybrid surgery both for proximal and distal revascularization in high-risk patients.	Low
	iv. Do not routinely use drains in the surgical wound.	Moderate
<b>Postoperative</b>		
14. Multimodal analgesia and opioid reduction strategies	Routinely use multimodal analgesic regimens to improve pain control and reduce opioid consumption.	High <sup>a</sup>
15. Oral feeding	Resume oral nutrition immediately postoperatively.	Moderate
16. Glycemic control	i. Glycemic goal of 180 mg/dL or less during the perioperative period.	Moderate
	ii. Routinely use diabetic and nutritional counseling as part of interdisciplinary care for diabetic patients.	High
17. Urinary drainage	Remove urinary drainage catheters before leaving the operating room.	Low
18. Early mobilization strategy	Use a formal plan for early mobilization immediately postoperatively, with early physical therapy involvement when needed.	Low
19. Discharge education	Utilize both written and verbal discharge education, use follow-up phone calls with 24-48 hours of hospital discharge, and arrange clinic follow-up with both the surgeon and primary care at least once by 30 days postoperatively.	Low <sup>a</sup>
	Confirm transition plan to outpatient podiatry and/or wound care center when relevant.	Moderate

HbA<sub>1c</sub>, Hemoglobin A<sub>1c</sub>; IV, intravenous; NSAID, non-steroidal anti-inflammatory drug; PONV, prevention of nausea and vomiting.

<sup>a</sup>Denotes some of the evidence is extrapolated from non-vascular patient cohorts.

Laboratory testing may identify a correctable cause for anemia (eg, iron deficiency). For example, in a large multi-center series of patients undergoing major elective surgery, including cardiac surgery, up to 60% of patients with anemia had low iron stores.<sup>34</sup> Subsequent treatment for iron deficiency can include either oral or intravenous routes, depending on the timeline to surgery, and there is evidence from one RCT and a pooled analysis of observational data from over 2500 patients to support that some patient populations may benefit from correction of iron deficiency, even with short courses of treatment.<sup>35,36</sup> Even though correction of anemia may reduce the need for transfusion, there is little evidence to support that it impacts overall morbidity and mortality, and there are no large studies to date to examine the effects in a vascular surgery-specific population.<sup>35,37-41</sup>

Caution is advised in translating certain anemia therapies to lower extremity revascularization amid presence

of the United States Food and Drug Administration's limitations of use of erythropoietin-stimulating agents in patients undergoing cardiac or vascular surgery, and an adverse event profile that includes thrombotic events.<sup>42</sup> Use of intraoperative interventions, such as minimally invasive techniques and/or cell salvage for complex cases anticipated to have long operative time, may also be considered in order to reduce the need for perioperative transfusion, particularly in patients with pre-existing anemia.<sup>43,44</sup>

**Suggestion:** Evaluate the cause of and treat chronic preoperative anemia.

**Quality of Evidence:** Low.

**2c. Frailty.** Frailty is a syndrome of diminished physiological reserve that predisposes patients to adverse health outcomes, especially in the presence of a stressor. Although frailty and aging are not the same, frailty is associated with aging and with the presence of PAD.



Loss of muscle mass, walking limitation, and inflammation compound frailty in PAD, and, depending on the frailty instrument used, the prevalence of frailty in patients with symptomatic PAD varies from 16% to 70%.<sup>45</sup> In a retrospective study of almost 140,000 patients measuring frailty using the Risk Analysis Index, 30-day mortality was significantly higher for frail patients after infrainguinal revascularization (nonfrail, 1.1%; frail, 6.3%; very frail, 9.4%), and frailty was highly predictive of 30-day postoperative mortality.<sup>46</sup> Frailty has also been shown to be associated with major complications after lower extremity bypass.<sup>47</sup> A prospective cohort study of patients with chronic limb-threatening ischemia (N = 643) undergoing endovascular or open revascularization found frailty (as measured by the clinical frail scale) associated with lower overall and amputation-free survival at 2 years.<sup>48</sup>

Specifically, a small RCT testing an outpatient comprehensive geriatric assessment and optimization program in elderly patients scheduled for elective aortic or infrainguinal bypass surgery was associated with reduced complications, shorter hospital LOS, and lower rate of patients discharged to a higher level of care dependency.<sup>49</sup> A patient who has a positive frailty screen should be followed up with a diagnostic assessment of frailty, and, when feasible, a comprehensive geriatric assessment with a tailored intervention. Based on observational data related to shared decision-making and/or prehabilitation experience from other cardiovascular conditions like aortic and carotid disease, these interventions seem advisable<sup>50</sup>; however, currently there are no published trials evaluating this for patients undergoing infrainguinal bypass.<sup>51</sup> Ultimately, variations in disease severity at presentation may limit feasibility or time available to undergo rehabilitation interventions, although it should be noted that even patients with ischemic wounds often do not need urgent revascularization.<sup>52-54</sup> In cases where urgent revascularization is required, the use of frailty screening may still be utilized to guide shared decision-making, consideration of alternate treatments that may still meet goals of care, or expectation setting around outcomes and recovery challenges.

*Suggestion:* Screen for frailty as a routine part of preoperative patient assessment.

*Quality of evidence:* Moderate.

**2d. Delirium risk.** Delirium can contribute to adverse events, prolonged hospital stays, non-home discharge destinations, and mortality following vascular surgery.<sup>55,56</sup> Delirium has been noted in medium- to large-size cohort studies utilizing validated delirium assessment scores to have incidences ranging from 5% to 29%<sup>57-63</sup>; rates as high as 42.3% have been identified in sub-cohorts of patients with chronic limb-threatening ischemia.<sup>64</sup> Risk factors identified from meta-analysis of observational studies include age, hypertension, diabetes, hearing impairment, history of transient ischemic

attack or cerebrovascular accident, renal failure, lower preoperative hemoglobin, duration of surgery, emergent surgery, and estimated blood loss, whereas regional anesthesia was protective from development of postoperative delirium.<sup>55</sup> A single moderate-sized prospective study of patients with chronic limb-threatening ischemia undergoing surgical therapy also noted an association of poor nutritional status (Short Nutritional Assessment Questionnaire for Residential Care [SNAQ-RC]  $\geq 3$ ) with delirium.<sup>56</sup> Preoperative identification of cognitive risk using standardized cognitive scales such as the mini-mental state exam can also allow engagement of patients/families to discuss implications of proposed surgery, including the capacity to consent and risk of postoperative complications including delirium and brain health.<sup>49,65</sup>

*Suggestion:* Screen for delirium risk and implement preoperative practices to minimize onset of delirium as a routine part of practice.

*Level of Evidence:* Low.

**2e. Psychosocial concerns.** Anxiety, depression, and lack of social support in particular are described risk factors in the course of recovery after surgery. A variety of studies have demonstrated that psychosocial factors play a significant role in recovery and are predictive of surgical outcomes in patients with PAD.<sup>66,67</sup> Estimates of depression in PAD patients range from 11% to 48% in cross-sectional studies and from 3% to 36% in longitudinal studies.<sup>68</sup> Depression is associated with progressive declines in walking ability, increased inflammation, and increased risk of recurrent symptoms.<sup>69-71</sup> A single-center retrospective cohort study of 216 patients undergoing infrainguinal revascularization found that patients with depression have worse primary patency (hazard ratio, 1.77; 95% confidence interval [CI], 1.03-3.02;  $P = .04$ ) and higher failure of revascularization (hazard ratio, 2.18; 95% CI, 1.22-3.88;  $P < .01$ ).<sup>70</sup> Among Veterans with PAD, concurrent depression was associated with a 13% greater major limb amputation and 17% greater mortality risk compared with patients with PAD without depression.<sup>72</sup> Patients who have a positive screening test should be referred back to their primary care physician or to a mental health specialist for formal diagnosis and treatment.

*Suggestion:* Routinely screen for depression.

*Quality of Evidence:* Low.

**2f. Tobacco and alcohol cessation.** Tobacco is a leading risk factor in the development of PAD and is associated with substantial short- and long-term morbidity and mortality.<sup>73,74</sup> In a cohort of 2913 patients from the Vascular Quality Initiative registry undergoing infrainguinal bypass surgery, current smoking was associated with almost 30% increased risk of major adverse limb events at 1 year.<sup>75</sup> In a multi-center retrospective review of 693 patients undergoing infrainguinal bypass surgery from 2013 to 2017, patients who smoked more than one

pack of cigarettes per day were at a 1.48-times increase in the risk of major adverse limb events at 1 year compared with patients who smoked less than one pack per day.<sup>76</sup> In the perioperative period, nicotine replacement therapy and smoking cessation medications have proven efficacy for smoking cessation, which is of critical importance in this specific patient population.<sup>77,78</sup> Further, a cluster-randomized trial of 156 current adult smokers with PAD demonstrated feasibility of a brief surgeon-delivered smoking cessation intervention increasing interest in smoking cessation and is associated with declines in nicotine dependence at 3 months.<sup>79,80</sup>

In addition to limb-based outcomes, there is substantial published literature describing other benefits to preoperative smoking cessation. A systematic review and meta-analysis of 25 studies (2 RCT, 7 prospective cohort studies, and 16 retrospective studies) including over 20,000 cardiac and non-cardiac surgical patients, there was a 23% and 47% reduction in respiratory complications in patients who stopped smoking 4 and 8 weeks prior to surgery, respectively.<sup>81</sup> Another meta-analysis of four RCTs demonstrated smoking cessation interventions reduced surgical site infections, and pooled data from 140 cohort studies supports 1 month of smoking cessation being associated with improved post-surgical outcomes.<sup>82,83</sup>

**Suggestion:** Prescribe smoking cessation therapy before surgery.

**Quality of evidence:** High.

In two RCTs comprising 69 surgical patients, 1 month of preoperative abstinence from alcohol improved outcomes in a patients who imbibed at least five alcohol equivalents (or 15 units) per day.<sup>84</sup> A Cochrane review of these two studies describes postoperative morbidity is increased by two- to three-fold in patients who abuse alcohol, and another meta-analysis of multiple RCTs in mixed surgical cohorts shows that daily drinking increases the risk of non-surgical site infection, but does not increase postoperative mortality.<sup>85</sup>

**Suggestion:** Recommend alcohol cessation 4 weeks prior to surgery.

**Quality of Evidence:** Low.

**2h. Medical risk.** Patients undergoing lower extremity bypass surgery generally have multiple cardiovascular, pulmonary, renal, and metabolic comorbidities that will influence their medical risk, impact their perioperative outcomes, and dictate a multidisciplinary approach to preoperative evaluation and optimization. Medical preoperative assessment and optimization of each major risk factor should be undertaken in accordance with the most current clinical practice guidelines on perioperative evaluation, optimization, and management of patients undergoing non-cardiac surgery. Risk scores may be used to help stratify overall risk of surgery, and the Vascular Quality Initiative (VQI) mortality prediction

model for patients with chronic limb-threatening ischemia performs well in American and European cohorts ( $C = 0.86$ ).<sup>86</sup>

**Cardiac risk.** Patients with PAD have a higher risk of cardiovascular mortality than patients with coronary artery disease alone.<sup>87</sup> Multiple cardiac risk calculators are available; however, the model discrimination for predicting postoperative myocardial infarction after surgery are not accurate at predicting postoperative outcomes, meaning they are unlikely to be of benefit and thus are not universally recommended.<sup>88-91</sup> In clinical practice, functional capacity or ability to perform metabolic equivalents is a key determinant of preoperative assessment.<sup>92</sup> Unfortunately, in patients with PAD and limited mobility, standard measures of activity may not be able to be used. Although poor capacity alone is only weakly associated with impaired outcomes after lower extremity bypass surgery, cardiac and pulmonary prognosis is good if functional capacity is high, even in the presence of stable ischemic heart disease or other risk factors.<sup>93</sup> Based on multiple RCTs and multi-society guidelines, to mitigate cardiac risk, all patients with peripheral vascular disease should be offered antiplatelet therapy (81 mg ASA), high-intensity HMG-CoA reductase inhibitors even if the low-density lipoprotein (LDL) cholesterol  $<100$  mg/dL, and antihypertensives where there is a persistent systolic blood pressure  $>140$  mmHg, unless contraindicated.<sup>92</sup> The Coronary Artery Revascularization Prophylaxis (CARP) trial<sup>94</sup> showed no survival benefit with coronary revascularization before elective vascular surgery, and another RCT<sup>95</sup> of 430 patients with high-risk cardiac stress tests showed no difference in long-term outcomes in elective vascular surgery with preoperative coronary revascularization. However, secondary analysis of the data from the CARP trial demonstrated that preoperative revascularization of left main coronary artery stenoses ( $\geq 50\%$ ) is associated with improved survival after elective vascular surgery.<sup>96</sup>

**Pulmonary risk.** There is an association of lower extremity atherosclerotic occlusive disease with chronic pulmonary disease due to its connection with current and prior nicotine abuse. There is no high-quality evidence on the effectiveness of routine preoperative chest radiography or pulmonary function tests in patients undergoing lower extremity bypass surgery.<sup>97</sup> Patients should only undergo these tests if they have new or unstable cardiopulmonary signs or symptoms, or if they are believed to be at such an increased risk of pulmonary complications that the results will alter management (ie, inform decisions or postpone surgery).<sup>98-100</sup>

**Suggestion:** Evaluate and optimize comorbidities prior to elective surgery and consider medical risks before urgent surgery.

**Quality of evidence:** High.

**2i. Glycemic control.** Over 20% of patients over 65 years have impaired fasting glucose, and up to one-third of

those patients do not carry a current diagnosis of diabetes.<sup>101</sup> Diabetes accelerates the progression of atherosclerosis<sup>102-104</sup> and is common in patients with peripheral artery disease and chronic limb-threatening ischemia.<sup>54,105</sup> There are conflicting reports of whether a diagnosis of diabetes alone adversely impacts outcomes after revascularization<sup>106-110</sup>; however, there is evidence to support that prolonged hyperglycemia as evidenced by an elevated hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) is associated with worse outcomes.<sup>102,111,112</sup> Retrospective analyses of patients undergoing revascularization with abnormal HbA<sub>1c</sub> (>7%) found that incremental increases in HbA<sub>1c</sub> is associated with increasing risk of overall complications, adverse limb events, and major amputation, regardless of whether patients had a prior diagnosis of diabetes.<sup>113,114</sup> Complications were particularly significant in patients with very elevated HbA<sub>1c</sub> values of >10%.<sup>114</sup>

Preoperative evaluation prior to lower extremity arterial bypass should include baseline HbA<sub>1c</sub> measurement.<sup>115,116</sup> Because prediabetes and diabetes are also frequently undiagnosed, baseline HbA<sub>1c</sub> measurement should be obtained regardless of a prior diagnosis of diabetes. For patients with elevated HbA<sub>1c</sub> and no existing medical care plan, referral to a specialist should be obtained. For those already on anti-hyperglycemic medication and an elevated HbA<sub>1c</sub>, particularly if it is >10%, there may be some benefit to attempts to improve hyperglycemic control prior to surgery.<sup>114</sup> Although there is no strong evidence to support a specific preoperative HbA<sub>1c</sub> level prior to revascularization in patients with PAD, attempts to obtain strict control (HbA<sub>1c</sub> <6%), as opposed to standard control (HbA<sub>1c</sub>, 7%-8%), in high-risk patients with diabetes was associated with worse outcomes in a randomized control trial of 10,251 patients with type 2 diabetes mellitus.<sup>117</sup> Therefore, the preoperative goal should be relative improvement in hyperglycemia and must be weighed against the urgency of the procedure.

Recommendations for preoperative management of specific anti-hyperglycemic regimens in type 2 diabetics varies based on the anticipated fasting time and invasiveness of the procedure.<sup>118</sup> Although a feature of enhanced recovery is reduced fasting time, given the invasiveness of lower extremity arterial bypass, most oral anti-hyperglycemic patients should be held the day of surgery. This is particularly true for patients on Metformin who will receive intravenous contrast exposure during the procedure. Depending on the specific insulin regimen, insulin doses should be continued as prescribed or a slightly reduced (80%) dose the day prior to surgery and then held or moderately reduced (50%) the day of surgery.<sup>118</sup>

**Suggestion:** All patients should have a baseline HbA<sub>1c</sub> level prior to revascularization. In patients with elevated HbA<sub>1c</sub> levels, anti-hyperglycemic treatment should be

initiated and/or titrated with the assistance of a specialist.

*Quality of Evidence:* High.

### 3. Perioperative antithrombotic strategy/plan

Based on an RCT and a prospective cohort study of over 1600 patients undergoing vascular surgery, aspirin reduces adverse cardiovascular events and mortality among patients with coronary artery disease and should be continued during the perioperative period.<sup>119-121</sup> Often, patients with coexistent coronary artery disease and PAD are on dual anti-platelet therapy, and based on multiple large observational studies of mixed surgical populations, the 2016 American College of Cardiology/American Health Association Guidelines recommend avoiding discontinuation of the second agent within 1 month after bare metal and 6 months after drug-eluting coronary stent placement.<sup>121-125</sup> When feasible, any anti-platelet medication other than aspirin must be stopped 7 days prior to surgery to reduce the risk of regional anesthesia techniques, and may be resumed 6 hours after block performance or epidural catheter removal.<sup>126,127</sup> Both warfarin and direct oral anticoagulants should be discontinued at least 5 days and 2 days in advance of surgery, respectively, to allow for regional anesthetic techniques and to reduce the risk of intra-operative bleeding.<sup>128</sup>

**Resuming antiplatelet and anticoagulation medications.** Little evidence is available on timing of perioperative resumption or initiation of anticoagulation and antiplatelet agents. The VOYAGER randomized control trial required randomization to therapy within 10 days post-procedure,<sup>129</sup> and the CASPAR trial maintained patients on aspirin and initiated clopidogrel in its therapy arm within 2 to 4 days postoperatively,<sup>130</sup> but published results from most other trials lack timing of post-operative initiation and focus on long-term risks of therapies. As detailed in the Global Vascular Guidelines on the Management of Chronic Limb-threatening Ischemia, risks and benefits of long-term medication regimens vary based on conduit type, disease stage, and the relative threat to bypass patency anticipated from anatomic and operative factors.<sup>54</sup>

In a Cochrane Review and meta-analysis of 16 studies with 5683 randomized patients, antiplatelet therapy had a beneficial effect on primary patency of bypass grafts compared with placebo or no therapy.<sup>131</sup> For vein bypasses, aspirin or dipyridamole monotherapy showed significant benefit in meta-analysis to primary graft patency only at 1 year (but not significant benefit at 1, 3, 6, or 24 months); in contrast, significant primary patency benefit was seen at all time points up through 1 year for prosthetic conduit bypasses. In the CASPAR trial, randomizing dual antiplatelet therapy of aspirin and clopidogrel vs aspirin and placebo for below-knee popliteal bypasses, vein bypasses did not have a patency benefit, whereas a significant benefit was observed in prosthetic



bypasses over median follow-up of just under 1 year.<sup>130</sup> An increase in bleeding events with dual antiplatelet therapy was seen for venous grafts but not prosthetic grafts.<sup>131</sup>

Differential benefits of postoperative anticoagulant therapy have been noted for venous bypasses and prosthetic bypasses in moderate-sized RCTs.<sup>132,133</sup> In meta-analysis of vitamin K antagonists therapy compared with no anticoagulant therapy, a significant protective benefit from occlusion was only seen at 6 months, but not at 3 months, or 1, 2, or 5 years in venous bypasses and only at a late interval (5 years) after prosthetic bypasses.<sup>134</sup> In venous bypasses at all time points from 3 to 24 months, vitamin K antagonists were protective against occlusion compared with aspirin or dipyridamole.<sup>134</sup> However, major hemorrhagic events occurred more frequently among patients undergoing femoropopliteal bypass receiving warfarin plus aspirin vs aspirin alone.<sup>135</sup> In a small RTC, postoperative hematoma was greater among those receiving warfarin and ASA compared with ASA alone, but no differences were noted between the groups in the number of packed red blood cells transfused, or in the incidence rate of overall non-hemorrhagic wound complications, or the overall complication rate.<sup>136</sup> The combination of warfarin plus aspirin therapy appears to protect from occlusion in smaller diameter prosthetic bypasses<sup>133</sup> and from severe ischemia in femoropopliteal PTFE grafts when occlusion occurs.<sup>137</sup>

Prospective randomized evidence to date around use of novel oral anticoagulant agents following lower extremity bypass revascularization comes primarily from the VOYAGER PAD trial,<sup>129</sup> which randomized initiation of rivaroxaban 2.5 mg twice daily dosing vs placebo in addition to background antiplatelet therapy; of note, clopidogrel as an adjunct to study antithrombotic regimen could be administered for up to 60 days after a lower extremity revascularization at the discretion of the investigator.<sup>138,139</sup> Among the 2185 patients who underwent surgical lower extremity intervention (lower extremity bypass, endarterectomy, or both), a benefit was seen with rivaroxaban in prevention of acute limb ischemia events.<sup>138</sup> The median time from revascularization to study drug initiation among the surgical revascularizations was 6 days, and bleeding risk of rivaroxaban appeared to be consistent between those initiated on medication therapy less than 6 days from surgery vs 6 or more days from surgery. Bleeding events requiring an unplanned take-back procedure remained low (1.3%) and did not differ between rivaroxaban vs placebo therapies; similarly, in the long term, by 3 years, the cumulative incidence of major bleeding did not differ between rivaroxaban vs placebo within the surgical bypasses.<sup>138</sup>

*Suggestion:* Continue aspirin throughout the perioperative period.

*Level of evidence:* High.

*Suggestion:* Consider adjunctive anticoagulation therapy in prosthetic or high-risk bypasses.

*Level of evidence:* Moderate.

## PREOPERATIVE RECOMMENDATIONS

**4. Fasting.** Based on meta-analysis of multiple RCTs in a range of surgical patients and according to both the American Society of Anesthesiologists' and European Society of Anesthesiology's preoperative fasting guidelines that give a strong recommendation based on high-quality evidence, patients should be allowed to drink clear fluids up to 2 hours before elective surgery, but should not eat any solid food for at least 6 hours for "light meals" or 8 hours for fatty foods and meat.<sup>140,141</sup> It is important to note that these recommendations apply to patients who undergo elective procedures, and a longer fasting period may be necessary in patients with risk factors for delayed gastric emptying such as obesity, diabetes, hiatal hernia, and gastroesophageal reflux disease.

*Suggestion:* Avoid overnight fasting; encourage clear fluids up to 2 hours and light foods up to 6 hours prior to the induction of general anesthesia.

*Level of evidence:* High.

**5. Carbohydrate loading.** Although the effectiveness of carbohydrate loading has not been fully established in patients undergoing vascular surgery, several RCTs in other surgical populations demonstrate a preoperative carbohydrate drink compared with placebo or fasting after midnight reduce insulin resistance and lessen the risk of hyperglycemia after surgery.<sup>142-148</sup> The most commonly studied preoperative carbohydrate regimen is 800 mL of a clear 12.5% carbohydrate drink the evening before surgery and 400 mL up to 2 hours before surgery.<sup>144-148</sup> A systematic review of 22 RCTs found that oral carbohydrate loading is safe up to 2 hours prior to surgery and can improve postoperative discomfort,<sup>149</sup> and a Cochrane Review of 27 RCTs of variable quality in mixed surgical populations conclude that preoperative carbohydrate loading reduces hospital length of stay.<sup>150</sup>

As many patients undergoing infrainguinal bypass have diabetes, the question of effectiveness and safety has been raised. It has been suggested that carbohydrate drink alternatives such as popular sports drinks may be more appropriate for patients with a diagnosis of diabetes; however, the evidence to support this practice is low.<sup>7</sup> Despite low quality evidence, it appears that oral carbohydrates are safe and effective in well-controlled diabetic patients, without a significant risk of hyperglycemia or aspiration.<sup>151,152</sup>

*Suggestion:* Patients without diabetes should receive a preoperative carbohydrate drink.

*Level of evidence:* High.

*Suggestion:* Patients with well-controlled diabetes should receive a preoperative carbohydrate drink.

*Level of evidence:* Low.

**6. Venous thromboembolism prophylaxis.** VTE risk can be significantly reduced by incorporating multiple strategies such as early mobility, mechanical prophylaxis, and chemoprophylaxis. Compiling data from over 100 RCTs of mixed populations comparing low-dose unfractionated heparin, low molecular weight heparin, and no chemoprophylaxis, the American College of Chest Physicians Guidelines on the prevention of venous thromboembolism (VTE) in nonorthopedic surgical patients notes that there is significant reduction in VTE when prophylactic doses of either of these anticoagulants are used and that bleeding complications are rare.<sup>153</sup>

The use of mechanical prophylaxis should be employed along with chemoprophylaxis or alone in patients who have a high risk of bleeding. Mechanical prophylaxis decreases the risk for postoperative VTE by preventing venous stasis and reducing plasminogen activator inhibitor-1, increasing endogenous fibrinolytic activity. Mechanical compression stockings should be avoided in patients with severe arterial disease despite intervention (systolic ankle pressure <60 mmHg; toe pressure <30 mmHg).<sup>154</sup> Intermittent pneumatic compression and venous foot pumps are not contraindicated in patients who have had infrainguinal bypass surgery, but mechanical prophylaxis should be avoided in patients with in situ bypasses, tibial bypass, or any other instance the compression device would place direct pressure on the conduit.<sup>155</sup>

*Suggestion:* Routinely use either low-dose unfractionated heparin or low molecular weight heparin with calf-length intermittent compression devices, when possible, starting either prior to surgery or within 24 hours of surgery end, and continuing throughout the hospitalization.

*Quality of literature:* High.

**7. Pre-anesthetic sedative and analgesia medication.** Preoperative anxiety is frequent and may lead to increased perioperative analgesic requirements. Multiple prospective and retrospective cohort studies demonstrate benzodiazepines can cause neurocognitive impairment and have unwanted sedative effects<sup>156-159</sup>; therefore, sedative or anxiolytic drugs should be avoided. This is particularly important in patients over 65 years old, as the American Geriatric Society has made a strong recommendation, with moderate evidence, against the use of benzodiazepines in older adults.<sup>157</sup>

Patients with PAD often have pre-existing chronic pain, due to ischemic rest pain and/or tissue loss, which are key features of this disease.<sup>160</sup> Perioperative pain management may be complicated by established analgesic regimens as well as advanced age

and pre-existing comorbidities including renal impairment.<sup>161</sup> Dosed appropriately for age and renal function, multimodal opioid-sparing perioperative analgesia includes acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and gabapentinoids, all of which have been shown to decrease postoperative pain scores, facilitate opioid sparing pain management, and can be administered in a cost-effective manner.<sup>159,162</sup>

Patients who are currently using analgesics for chronic pain could benefit from an interdisciplinary approach and should have expectations set for postoperative pain management before the operation occurs. Abruptly stopping the patient's baseline opioid medication can result in inadequate postoperative pain control and increased risk of acute withdrawal in the postoperative period, and this is not recommended.<sup>163</sup> This is particularly true for patients taking methadone.<sup>164</sup>

For patients on buprenorphine (especially >12 mg/day), even dose decreases can cause withdrawal, and patients will need their pain specialist to gradually reduce the dose prior to any operation in which postoperative opioids will be used.<sup>165</sup>

Notably, revascularization may improve chronic ischemic pain, and outpatient tapers of all types of analgesics may be possible.

*Suggestion:* Do not routinely use sedatives to reduce anxiety preoperatively.

*Level of evidence:* Low.

*Suggestion:* Routinely use preoperative administration of acetaminophen, NSAIDs, and gabapentinoids as part of a multimodal opioid-sparing analgesia strategy.

*Level of evidence:* Low.

*Suggestion:* Continue existing preoperative pain regimens with minimal disruption.

*Level of evidence:* Moderate.

**8. Antimicrobial prophylaxis and skin preparation to reduce surgical site infections.** Surgical site infections (SSIs) can involve superficial or deep incisional tissues, and are typically caused by typical skin flora, although vascular surgical wounds and/or ischemic wounds can have a variety of organisms.<sup>166</sup> A bundled program to prevent the development of SSI is often recommended and may reduce SSI by 51% in a single-center observational study.<sup>167</sup> Specifically included in most bundles are perioperative normothermia, appropriate skin preparation and hair removal, preoperative antibiotic prophylaxis, and minimizing traffic in and out of the operating room.<sup>168</sup> Adjunctive use of antibiotics such as triclosan-coated suture or gentamicin-impregnated grafts have mixed results and have not been shown to consistently reduce SSIs.<sup>169,170</sup>

Skin preparation should be standardized, with the operative area being scrubbed on the day prior to and

immediately before surgery with a Chlorhexidine solution based on RCTs of heterogeneous clean-contaminated surgeries indicating benefit, though smaller RCTs and prospective observational studies of vascular reconstructions have not demonstrated benefit.<sup>171-173</sup> Based on meta-analysis of a small number of RCTs with heterogeneous surgical procedures and quasi-experimental cohort studies of vascular surgeries, hair clipping should be performed immediately preoperatively, with hair clipping preferred to shaving.<sup>167,174,175</sup>

Preoperative intravenous prophylactic antibiotics should be administered immediately prior to lower extremity bypass based on meta-analysis of RCTs.<sup>176</sup> Antibiotic duration has been primarily evaluated in patients without pre-existing infectious sources; in lower extremity bypass procedures with non-infected tissue, prophylactic antibiotics did not convey significant additional benefit when continued more than 24 hours postoperatively.<sup>176</sup> Extrapolated from cardiac and spine surgery, intraoperative antibiotic should be re-dosed within two serum half-lives of the agent<sup>177-179</sup> and may be additionally recommended for substantive procedural blood loss.<sup>180</sup>

*Suggestion:* Consider the use of bundles programs to reduce SSIs.

*Quality of Evidence:* Low.

*Suggestion:* Prophylactic intravenous antibiotic dosing should begin 30 to 60 minutes preoperatively with redosing intraoperatively within two serum half-lives of antimicrobial agent used or with substantive intraoperative blood loss, and extending no more than 24 hours postoperatively.

*Quality of evidence:* High.

**9. Prevention of nausea and vomiting.** Postoperative nausea and vomiting (PONV) is estimated to be 50% and 30% in the general surgical population, respectively, and may approach 80% in patients who are high risk for PONV.<sup>181</sup> The most commonly used PONV risk scoring systems are the Koivuranta and Apfel scores.<sup>182,183</sup> It is important to employ PONV mitigation strategies, such as minimizing the use of nitrous oxide and volatile anesthetics,<sup>184</sup> utilizing regional anesthesia such as peripheral nerve blocks and neuraxial anesthesia,<sup>185</sup> and including opioid-sparing, multimodal analgesia techniques.<sup>186,187</sup>

There is significant high quality evidence from multiple RCTs supporting the use of multimodal prophylaxis and treatment of PONV that can be generalized to major vascular surgery.<sup>188</sup> Pharmacologic agent classes and other interventions that are currently available include 5-HT<sub>3</sub> receptor antagonists, corticosteroids, antihistamines, dopamine antagonists, propofol anesthesia, NK-1 receptor antagonists, anticholinergics, and acupuncture.<sup>189</sup> For rescue treatment, one should use an anti-emetic from different class than what was used for prophylaxis.

*Suggestion:* Risk assess for PONV, routinely use multimodal PONV prophylaxis based on assessment, and use PONV rescue with a different class of anti-emetic.

*Quality of evidence:* High.

## INTRAOPERATIVE RECOMMENDATIONS

### 10. Anesthetic protocol

Patients undergoing peripheral vascular procedures often have widespread atherosclerotic disease and suffer significantly from cardiac complications and death, mandating hemodynamic stability throughout surgery.<sup>190,191</sup>

Although the role of regional anesthesia in ERAS has gained interest in recent years, there remains no clear evidence favoring regional (spinal, epidural, or peripheral nerve blockade) or general anesthesia over the other. Individual studies have suggested specific benefits from regional anesthesia: these include attenuation of the neuroendocrine response to surgery,<sup>192</sup> reduction in blood loss,<sup>193</sup> improvement in pulmonary function,<sup>194</sup> reduction in myocardial ischemia,<sup>195</sup> enhancement of lower limb blood flow,<sup>196</sup> and reduction the incidence of graft thrombosis and thrombotic response to surgery.<sup>197,198</sup> Evidence of possible long-term benefit from regional anesthesia remains elusive, and there are data to suggest that the type of anesthesia given for peripheral vascular surgery does not significantly affect cardiac morbidity or mortality, overall mortality, or LOS.<sup>193,198-200</sup> However, an RCT of 50 patients found fewer intraoperative episodes of myocardial ischemia in patients undergoing infra-inguinal bypass surgery under combined femoral and sciatic nerve blockade compared with general anesthesia.<sup>201</sup>

Whether choosing a regional or general anesthesia approach, the intraoperative analgesic strategy should include at least one or two simple non-opioid analgesics such as acetaminophen, NSAIDs, an  $\alpha_2$ -agonist, or ketamine.<sup>202</sup>

*Summary/Recommendation:* Use a multimodal analgesic strategy that includes non-opioid analgesics and regional anesthesia tailored the expected duration of pain and postoperative course.

*Quality of evidence:* Moderate.

### 11. Goal-directed fluid therapy

Intraoperative fluid management is a fundamental part of enhanced recovery programs, and both hypovolemia and hypervolemia have been strongly associated with significant postoperative complications. These include: impaired peripheral organ perfusion, site infection, poor wound healing, tissue edema, fluid overload, acute kidney injury and sepsis, as well as increased morbidity and mortality, and longer hospital stay in patients undergoing major abdominal and colorectal surgery.<sup>203-205</sup> Several systematic reviews and meta-analyses including observational studies and RCTs have shown that goal-

directed fluid therapy decreases postoperative morbidity and mortality in surgical patients,<sup>206</sup> as well as reduces both the volume of fluids administered and the incidence of complications, while still protecting renal function.<sup>205</sup>

Patients presenting for infrainguinal arterial operations are fundamentally physiologically different from the general cohort of patients presenting for major abdominal and colorectal surgery; they are often older with multiple coexisting comorbidities. Furthermore, the nature of surgery is different. Subgroup analysis has shown no evidence to support the use of goal-directed fluid therapy in peripheral vascular surgery patients; however, basic physiological principles apply to this high-risk group of patients. Avoidance of intraoperative hypotension, defined as a 40% decrease from pre-induction mean arterial blood pressure with a cumulative duration of more than 30 minutes, and prevention of fluid overload are fundamental to avoiding adverse outcomes in this patient group.<sup>207,208</sup>

*Suggestion:* Routinely use cardiac monitoring (arterial line and non-invasive cardiac output monitoring such as stroke volume variation) to support euvolemia.

*Quality of evidence:* Low.

## 12. Body temperature management

Perioperative hypothermia (core body temperature <36 °C) is a result of cold operating room temperatures, exposure of the patient, and anesthesia-related impairment of central thermoregulatory control. Hypothermia leads to cardiac arrhythmias, coagulopathies, altered levels of consciousness, decreased drug metabolism, impaired renal function, leftward shift in the hemoglobin oxygen saturation curve, resulting in reduced oxygen delivery, and prolonged wound healing and increased SSIs. From a combination of RCTs and prospective and retrospective cohorts across many surgical specialties, there is evidence that maintaining normothermia reduces these undesired outcomes.<sup>209</sup> Strategies to maintain normothermia include preoperative warming (10 to 30 minutes prior to induction of anesthesia), intraoperative warming with a forced air heating blanket, and use of fluid warmers and pre-warmed irrigation.<sup>209</sup>

*Suggestion:* Use multiple strategies to maintain normothermia, including prewarming and active warming of patients intraoperatively.

*Quality of evidence:* Moderate.

## 13. Surgical access and techniques

**Autologous blood salvage.** In contrast to recommendations for aortic surgery,<sup>2,210-212</sup> there is insufficient evidence to recommend routine use of autologous blood salvage in lower extremity bypass cases, due to typically lower operative losses associated with these infrainguinal procedures.<sup>43,44,213</sup>

**Groin incisions and closure.** Groin incisions are prone to infections and surgical morbidity, and reported rates in literature range widely from approximately 3% to 30%.<sup>214,215</sup> A Cochrane Review of two RCTs that included 283 groin incisions found with low certainty that transverse incisions for the exposure of the common femoral artery resulted in fewer SSIs.<sup>216</sup> Another meta-analysis that included the same 2 RCTs and added 5 case-control studies compared transverse with longitudinal incisions in 5922 groins and found that transverse incisions had significantly lower incidence of surgical site infection (0.73% vs 3.68%;  $P = .03$ ) and wound dehiscence, but that lymphatic complications were similar (8.58% vs 10.9%;  $P = .87$ ).<sup>217</sup>

Multiple techniques are described in literature to optimize groin closure to reduce the risk for SSIs. A systematic review of eight RCTs shows that use of plastic adhesive skin coverings with or without antimicrobial properties does not reduce the incidence of SSIs.<sup>218</sup> Meta-analysis of 17 RCTs and seven observational studies noted that subcuticular sutures for skin closure had a significant reduction in SSI rates when compared with surgical clips or transdermal sutures (odds ratio, 0.33; 95% CI, 0.17-0.65;  $P = .001$ ).<sup>219</sup> When evaluating adjuncts to closure, closed incision negative pressure wound therapy significantly reduced the risk of SSI compared with standard dressings (odds ratio, 0.34; 95% CI, 0.23-0.51;  $P < .001$ ).<sup>219</sup> Use of local antibiotics, fibrin glue, silver alginate dressings, and platelet-rich plasma have inconsistent results, but have not shown any statistically significant effects on SSI rates in metanalysis.<sup>219-223</sup>

Similarly, a Cochrane Review of three RCTs demonstrates there is no evidence usage of drains will decrease groin incision complications.<sup>224</sup>

Patients at high risk for groin incisional complications (females, patients with obesity, patients with end-stage renal disease) may benefit from prophylactic sartorius muscle flap closure.<sup>225,226</sup> Although incisional breakdown was similar between the groups, the presence of a vascularized muscle flap overlying the vascular repair was associated with reduced need for reoperation and allowed more wounds to be managed with local wound care alone.

*Suggestion:* Avoid the use of drains in groin incisions.

*Level of Evidence:* Moderate.

*Suggestion:* When possible, use transverse groin incisions. Close groin incisions with subcuticular sutures and use a negative-pressure dressing.

*Level of Evidence:* Low.

**Vein harvest.** Along with the choice of conduit, the technique of vein harvest is equally critical. The largest retrospective study used the VQI database and evaluated 5066 patients from 2003 to 2013. Single continuous incision was used in 48.6%, skip incisions were used in 39.7%,



and endoscopic vein harvest was used in 12.7%. There was no difference in SSIs in the three groups, but there was a statistically significant reduction in patency of endoscopically harvested veins at 1 year.<sup>227</sup> Other retrospective studies have also demonstrated a reduction in patency of endoscopically harvested veins when used for lower extremity bypass.<sup>228,229</sup>

**Suggestion:** Harvest vein conduits with either continuous or skip open incisions rather than endoscopic harvest.

**Level of evidence:** Low.

**Hybrid surgery.** Hybrid surgery has had a rapid increase in the treatment of PAD and should be considered in patients who are high risk for traditional open surgery, but have lesions that may not be completely amenable to endovascular intervention.<sup>230</sup> Although hybrid surgery is increasingly utilized, the population is very heterogeneous, and the data are limited, which reinforces the importance of case selection and treating patients with complex PAD at centers equally capable of both open and endovascular approaches. The most commonly described hybrid infrainguinal revascularization is a common femoral artery endarterectomy with endovascular revascularization of the femoropopliteal artery segment. A retrospective study of 4478 patients undergoing either venous bypass or prosthetic bypass or hybrid revascularization found that patients that are submitted to a hybrid intervention are older than the other groups and more likely to be treated under regional anesthesia. Compared with those undergoing a hybrid approach, prosthetic bypass was associated with more deep SSIs, organ space SSI, postoperative sepsis, and unplanned 30-day readmission, and vein bypasses were associated with more superficial SSIs.<sup>231</sup> Similarly, a retrospective analysis of 1480 patients from the National Surgical Quality Improvement Program registry demonstrated superior short-term outcomes, especially with reduction of SSIs, with a hybrid approach.<sup>232</sup> A retrospective analysis of 850 propensity-matched patients from the VQI demonstrated that hybrid revascularization was associated with a lower rate of myocardial infarction and renal complications, shorter hospital LOS, and higher rate of discharge to home compared with bypass.<sup>230</sup> The 1-year outcomes suggested that patients in the bypass group had a higher likelihood of improvement in ambulatory status compared with patients in the hybrid group (16.7% vs 7.7%;  $P = .044$ ); however, survival analysis showed no difference in overall survival or amputation-free survival between the two groups. A non-randomized prospective study of infrainguinal hybrid revascularization in 99 patients with chronic limb-threatening ischemia demonstrates high technical success rates, and patency at 2.5 years matches that of other reported infrainguinal bypasses.<sup>233</sup>

**Suggestion:** Hybrid surgery and distal endovascular revascularization can be considered in older patients and may reduce SSIs.

**Level of evidence:** Low.

## POSTOPERATIVE RECOMMENDATIONS

### 14. Multimodal analgesia and opioid reduction.

Regional anesthesia is thought to be superior to general anesthesia for early acute postoperative pain management and side effects; however, the evidence for improved patient satisfaction is limited.<sup>234</sup> There is good quality evidence to support multimodal analgesia for postoperative pain relief following surgery.<sup>187</sup> These techniques combine regional anesthetic techniques and non-opioid analgesics at multiple points in the pain pathway.<sup>235</sup> A Cochrane review identified a 20% to 25% reduction in pain intensity and a 30% to 50% reduction in analgesic consumption in surgical patients treated with a multi-modal strategy.<sup>236</sup> The use of clonidine is associated with reductions in pain, opioid consumption, and early postoperative nausea and vomiting.<sup>237</sup>

Acute pain management in vascular surgery patients with underlying chronic ischemic pain can often be challenging particularly in the postoperative period. One 30-day postoperative follow-up study showed that 61.3% of preoperative opioid users and 28.4% of opioid-naïve patients continued using opioids.<sup>238</sup> Given a 35% prevalence of chronic opioid use among patients with PAD and because revascularization often eliminates ischemic pain, a concerted effort should be made to taper existing pain medications.<sup>239</sup>

**Suggestion:** Routinely use multimodal analgesic regimens to improve pain control and reduce opioid consumption.

**Level of Evidence:** High.

**15. Oral feeding.** Postoperatively, patients should be encouraged to reestablish oral nutrition as early as possible, allowing patients to eat what they feel comfortable with and consume oral nutritional supplements daily. Patients with chronic limb-threatening ischemia undergoing either endovascular or open revascularization that have improved postoperative nutritional status fared better, even when their baseline nutritional status was poor.<sup>13</sup>

**Suggestion:** Resume oral nutrition as early as possible, if not immediately postoperatively, allowing patients to eat what they feel comfortable with and consume oral nutritional supplements daily.

**Level of Evidence:** Moderate.

**16. Glycemic control.** Patients may benefit from incorporating a dietician to provide nutritional counseling, a nurse diabetic educator, and endocrinology for patients who have known diabetes mellitus. Perioperative hyper-



glycemia in vascular surgery patients has previously been defined as a glucose value of greater than 180 mg/dL within 72 hours of surgery.<sup>240</sup> The presence of perioperative hyperglycemia is strongly associated with increased 30-day mortality (5.7% vs 0.7%;  $P < .01$ ), SSIs (5.7% vs 2.6%;  $P = .01$ ), increased rates of renal failure, postoperative stroke, and need for readmission.<sup>240</sup> The prevalence of peripheral arterial disease in patients with diabetes mellitus is estimated to be 29%, with amputation rates in diabetic patients being five to 10 times higher than in non-diabetic patients.<sup>54,241</sup> Improving glycemic control provides for reduced numbers of SSIs, facilitates wound healing, and provides better patient outcomes. Even in the absence of a known diagnosis, most guidelines support starting insulin therapy intraoperatively and postoperatively for a blood glucose of  $>180$  g/dL in supported hospitalized patients with a target of between 140 and 180 g/dL for most patients.<sup>242,243</sup> Careful postoperative glycemic control to limit extreme variability in glucose decreases adverse cardiac events<sup>244</sup>; however, caution is advised as aggressive treatment causing hypoglycemia may increase mortality.<sup>117,245</sup>

*Suggestion:* Glycemic goal of 180 mg/dL or less during the perioperative period.

*Quality of evidence:* Moderate.

*Suggestion:* Routinely use diabetic and nutritional counseling as part of interdisciplinary care for diabetic patients.

*Quality of evidence:* High.

**17. Urinary drainage.** Due to concern of catheter-associated urinary tract infection and guidance from the United States Centers for Disease Control and Prevention, the use of prolonged urinary catheters has decreased.<sup>246</sup> Although urinary catheters are often needed intraoperatively, there is little need for continuous postoperative urine output monitoring after lower extremity bypass, and catheters should be removed at the end of the operation, or as soon as possible in extenuating circumstances.

*Suggestion:* Remove urinary drainage catheters before leaving the operating room, or as soon as possible in extenuating circumstances.

*Level of evidence:* Low.

**18. Early mobilization.** PAD, and especially the more severe chronic limb-threatening ischemia, can lead to a significant decrease in a patient's baseline functional status. Evaluating the baseline functional status and setting appropriate goals and expectations is imperative to a successful postoperative mobility plan, and is associated with long-term independence and survival.<sup>247</sup> Clear communication of weight-bearing restrictions and immediate availability of appropriate off-loading shoes for patients with tissue loss who can partially or fully weight bear avoids delay in postoperative

mobilization. Mobility is not necessarily limited to ambulation, and especially for those who are non-weight bearing, can include any active limb exercise. Depending on the patient's clinical condition, this could consist of simple interventions such as dynamic range of motion, sitting at the side of the bed, or pivoting to a bedside chair.<sup>248</sup> Successful mobilization strategies require a multidisciplinary approach, objective evaluation of patient safety and ability for early ambulation, and tracking progress with a formal mobility scale.<sup>249</sup> If patients are not progressing, then causes of failure need to be analyzed by the multidisciplinary team, including physical therapists, and corrective measures should be instituted quickly. Multi-disciplinary care teams for vascular surgery patients have demonstrated improved outcomes when incorporating podiatry and wound care centers.<sup>250,251</sup>

*Suggestion:* Use a formal plan for early mobilization immediately postoperatively, with early physical therapy involvement when needed.

*Level of evidence:* Low.

### 19. Discharge criteria and post discharge education.

Patients undergoing vascular surgery have 30-day readmission rates as high as 20% and up to one-half of readmissions are deemed avoidable.<sup>252-254</sup> In line with fundamental ERAS philosophy, there is a published conceptual model of preventing readmissions in vascular surgery that includes patient education and timely communication from the preoperative phase to the postoperative phase of care.<sup>4</sup> A Cochrane Review of two RCTs concluded that written and verbal information on specific care instructions, medication lists, and when to seek medical attention at discharge significantly increased patient knowledge and satisfaction.<sup>255,256</sup> The data on follow-up postoperative phone calls has been mixed; a Cochrane Review of 33 studies of mixed methodology from different specialties was inconclusive; however, no adverse effects of the intervention were reported.<sup>257</sup>

*Suggestion:* Utilize both written and verbal discharge education, use follow-up phone calls with 24 to 48 hours of hospital discharge, and arrange clinic follow-up with both the surgeon and primary care at least once at 30 days postoperatively.

*Level of evidence:* Low.

## SUMMARY AND CONCLUSION

The main purpose of this consensus statement is to provide a framework from which to build a multidisciplinary program to implement best perioperative practices for patients undergoing lower extremity vascular bypass surgery. As demonstrated in other specialties, forming care teams to enhance patient optimization and shared decision-making, focus on physiologic stress minimization, and reduce variation in

postoperative convalescence promises to improve the safety and outcomes for patients undergoing infrainguinal bypass operations.

This consensus statement defines current standards based on the available medical literature, but there are many gaps in the published medical knowledge specific to this high-risk group of patients. Of the 36 practice suggestions made, only 11 are based on high-quality evidence. Although the few clinical studies available seem promising, studies of high methodological quality are needed. The lines of research to be developed could include any of the ERAS elements or combined elements, but are particularly needed in pre-admission optimization, prehabilitation, preoperative carbohydrate loading in diabetics, pre-anesthetic sedatives and analgesia, early mobility protocols, and post-discharge education.

### AUTHOR CONTRIBUTIONS

Conception and design: KM, OL, HD

Analysis and interpretation: KM, ES, KA, SA, AS, MT, KD, IS, MD, CS, RU, SH, JS, OL, HD

Data collection: KM, ES, KA, SA, AS, MT, KD, IS, MD, CS, RU, SH, JS, OL, HD

Writing the article: KM, ES, KA, SA, AS, MT, KD, IS, MD, CS, RU, SH, JS, OL, HD

Critical revision of the article: KM, ES, KA, SA, AS, MT, KD, IS, MD, CS, RU, SH, JS, OL, HD

Final approval of the article: KM, ES, KA, SA, AS, MT, KD, IS, MD, CS, RU, SH, JS, OL, HD

Statistical analysis: Not applicable

Obtained funding: Not applicable

Overall responsibility: KM

### REFERENCES

1. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. *JAMA Surg* 2017;152:292-8.
2. McGinigle KL, Spangler EL, Pichel AC, Ayyash K, Arya S, Settembrini AM, et al. Perioperative care in open aortic vascular surgery: a consensus statement by the enhanced recovery after surgery (ERAS) society and society for vascular surgery. *J Vasc Surg* 2022;75:1796-820.
3. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. *Br J Anaesth* 1997;78:606-17.
4. Brooke BS, De Martino RR, Girotti M, Dimick JB, Goodney PP. Developing strategies for predicting and preventing readmissions in vascular surgery. *J Vasc Surg* 2012;56:556-62.
5. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
6. McGinigle KL, Eldrup-Jorgensen J, McCall R, Freeman NL, Pascarella L, Farber MA, et al. A systematic review of enhanced recovery after surgery for vascular operations. *J Vasc Surg* 2019;70:629-40.e1.
7. Witcher A, Axley J, Novak Z, Laygo-Prickett M, Guthrie M, Khaja A, et al. Implementation of an enhanced recovery program for lower extremity bypass. *J Vasc Surg* 2021;73:554-63.
8. Forsmo HM, Erichsen C, Rasdal A, Tvinnereim JM, Körner H, Pfeiffer F. Randomized controlled trial of extended perioperative counseling in enhanced recovery after colorectal surgery. *Dis Colon Rectum* 2018;61:724-32.
9. de Aguiar-Nascimento JE, Leal FS, Dantas DCS, Anabuki NT, de Souza AMC, Silva E Lima VP, et al. Preoperative education in cholecystectomy in the context of a multimodal protocol of perioperative care: a randomized, controlled trial. *World J Surg* 2014;38:357-62.
10. Grawe JS, Mirow L, Bouchard R, Lindig M, Huppe M. Impact of preoperative patient education on postoperative pain in consideration of the individual coping style. *Schmerz* 2010;24(6 SRC - BaiduScholar):575-86.
11. Gonzalez L, Kassem M, Owora AH, Seligson MT, Richards CY, Monita MM, et al. Frailty and biomarkers of frailty predict outcome in veterans after open and endovascular revascularization. *J Surg Res* 2019;243:539-52.
12. Bath J, Smith JB, Woodard J, Kruse RL, Vogel TR. Complex relationship between low albumin level and poor outcome after lower extremity procedures for peripheral artery disease. *J Vasc Surg* 2021;73:200-9.
13. Shiraki T, Takahara M, Iida O, Soga Y, Kodama A, Miyashita Y, et al. Baseline and updated information on nutritional status in patients with chronic limb threatening ischaemia undergoing revascularisation. *Eur J Vasc Endovasc Surg* 2021;61:467-72.
14. Garcia-Rivera E, San Norberto EM, Fidalgo-Domingos L, Revilla-Calavia A, Estevez-Fernandez I, Cenizo-Revuelta N, et al. Impact of nutritional and inflammatory status in patients with critical limb-threatening ischemia. *Int Angiol* 2021;40:504-11.
15. Mii S, Guntani A, Kawakubo E, Shimazoe H, Ishida M. Preoperative nutritional status is an independent predictor of the long-term outcome in patients undergoing open bypass for critical limb ischemia. *Ann Vasc Surg* 2020;64:202-12.
16. Furuyama T, Yamashita S, Yoshiya K, Kurose S, Yoshino S, Nakayama K, et al. The controlling nutritional status score is significantly associated with Complete ulcer healing in patients with critical limb ischemia. *Ann Vasc Surg* 2020;66:510-7.
17. Breen L, Stokes KA, Churchward-Venne TA, Moore DR, Baker SK, Smith K, et al. Two weeks of reduced activity decreases leg lean mass and induces "anabolic resistance" of myofibrillar protein synthesis in healthy elderly. *J Clin Endocrinol Metab* 2013;98:2604-12.
18. Lobo DN, Gianotti L, Adiamah A, Barazzoni R, Deutz NEP, Dhatriya K, et al. Perioperative nutrition: recommendations from the ESPEN expert group. *Clin Nutr (Edinburgh, Scotland)* 2020;39:3211-27.
19. Weimann A, Braga M, Carli F, Higashiguchi T, Hubner M, Klek S, et al. ESPEN guideline: clinical nutrition in surgery. *Clin Nutr (Edinburgh, Scotland)* 2017;36:623-50.
20. Moya P, Miranda E, Soriano-Irigaray L, Arroyo A, Aguilar M-D-M, Bellon M, et al. Perioperative immunonutrition in normo-nourished patients undergoing laparoscopic colorectal resection. *Surg Endosc* 2016;30:4946-53.
21. Moya P, Soriano-Irigaray L, Ramirez JM, Garcea A, Blasco O, Blanco FJ, et al. Perioperative standard oral nutrition supplements versus immunonutrition in patients undergoing colorectal resection in an enhanced recovery (ERAS) protocol: a multicenter randomized clinical trial (SONVI study). *Medicine* 2016;95:e3704.
22. Buzquurz F, Bojesen RD, Grube C, Madsen MT, Gogenur I. Impact of oral preoperative and perioperative immunonutrition on postoperative infection and mortality in patients undergoing cancer surgery: systematic review and meta-analysis with trial sequential analysis. *BJS Open* 2020;4:764-75.
23. Waitzberg DL, Saito H, Plank LD, Jamieson GG, Jagannath P, Hwang T-L, et al. Postsurgical infections are reduced with specialized nutrition support. *World J Surg* 2006;30:1592-604.
24. Jie B, Jiang Z-M, Nolan MT, Zhu S-N, Yu K, Kondrup J. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. *Nutrition* 2012;28:1022-7.
25. McClave SA, Kozar R, Martindale RC, Heyland DK, Braga M, Carli F, et al. Summary points and consensus recommendations from the North American surgical nutrition summit. *JPEN J Parenter Enteral Nutr* 2013;37(5 Suppl):99S-105S.
26. Stoppe C, Goetzenich A, Whitman G, Ohkuma R, Brown T, Hatzakorzian R, et al. Role of nutrition support in adult cardiac surgery: a consensus statement from an international multidisciplinary expert group on nutrition in cardiac surgery. *Crit Care* 2017;21:131.
27. Nandhra S, Boylan L, Prentis J, Nesbitt C, Northern Vascular C. The influence of preoperative anemia on clinical outcomes after infrainguinal bypass surgery. *Ann Vasc Surg* 2020;66:586-94.

28. Bodewes TCF, Pothof AB, Darling JD, Deery SE, Jones DW, Soden PA, et al. Preoperative anemia associated with adverse outcomes after infrainguinal bypass surgery in patients with chronic limb-threatening ischemia. *J Vasc Surg* 2017;66:1775-85.e2.
29. Baron DM, Hochrieser H, Posch M, Metnitz B, Rhodes A, Moreno RP, et al. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients. *Br J Anaesth* 2014;113:416-23.
30. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. *Lancet* 2011;378:1396-407.
31. Spahn DR, Goodnough LT. Alternatives to blood transfusion. *Lancet* 2013;381:1855-65.
32. Isbister JP, Shander A, Spahn DR, Erhard J, Farmer SL, Hofmann A. Adverse blood transfusion outcomes: establishing causation. *Transfus Med Rev* 2011;25:89-101.
33. Munoz M, Acheson AG, Auerbach M, Besser M, Habler O, Kehlet H, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. *Anaesthesia* 2017;72:233-47.
34. Munoz M, Laso-Morales MJ, Gomez-Ramirez S, Cadellas M, Nunez-Matas MJ, Garcia-Erce JA. Pre-operative haemoglobin levels and iron status in a large multicentre cohort of patients undergoing major elective surgery. *Anaesthesia* 2017;72:826-34.
35. Spahn DR, Schoenrath F, Spahn GH, Seifert B, Stein P, Theusinger OM, et al. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. *Lancet* 2019;393:2201-12.
36. Munoz M, Gomez-Ramirez S, Cuenca J, Garcia-Erce JA, Iglesias-Aparicio D, Haman-Alcober S, et al. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. *Transfusion* 2014;54:289-99.
37. Guinn NR, Guercio JR, Hopkins TJ, Grimsley A, Kurian DJ, Jimenez MI, et al. How do we develop and implement a preoperative anemia clinic designed to improve perioperative outcomes and reduce cost? *Transfusion* 2016;56:297-303.
38. Enko D, Wallner F, von-Goedecke A, Hirschmugl C, Auersperg V, Halwachs-Baumann G. The impact of an algorithm-guided management of preoperative anemia in perioperative hemoglobin level and transfusion of major orthopedic surgery patients. *Anemia* 2013;2013:641876.
39. Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. *Br J Anaesth* 2011;106:13-22.
40. Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. *Eur J Anaesthesiol* 2017;34:332-95.
41. Janssen TL, Steyerberg EW, van Gammeren AJ, Ho GH, Gorbardhan PD, van der Laan L. Intravenous iron in a prehabilitation program for older surgical patients: prospective cohort study. *J Surg Res* 2021;257:32-41.
42. Administration USFaD. Epogen (epoetin alfa) injection, for intravenous or subcutaneous use. Drug label. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/103234s5363s53661b1.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s53661b1.pdf). Accessed September 28, 2020.
43. Frank SM, Sikorski RA, Konig G, Tsilimigras DI, Hartmann J, Popovsky MA, et al. Clinical utility of autologous salvaged blood: a review. *J Gastrointest Surg* 2020;24:464-72.
44. Tawes RL Jr, Scribner RG, Duval TB, Beare JP, Sydorak GR, Rosenman JE, et al. The cell-saver and autologous transfusion: an underutilized resource in vascular surgery. *Am J Surg* 1986;152:105-9.
45. Drudi LM, Ades M, Mancini R, Boudrias C, Obrand DI, Steinmetz OK, et al. Frailty assessment in older adults undergoing interventions for peripheral arterial disease. *J Vasc Surg* 2019;70:1594-602.e1.
46. Rothenberg KA, George EL, Trickey AW, Barreto NB, Johnson TM 2nd, Hall DE, et al. Assessment of the risk analysis index for prediction of mortality, major complications, and length of stay in patients who underwent vascular surgery. *Ann Vasc Surg* 2020;66:442-53.
47. Eslami MH, Saadeddin Z, Rybin DV, Doros G, Siracuse JJ, Farber A. Association of frailty index with perioperative mortality and in-hospital morbidity after elective lower extremity bypass. *J Vasc Surg* 2019;69:863-74.e1.
48. Takeji Y, Yamaji K, Tomoi Y, Okazaki J, Tanaka K, Nagae A, et al. Impact of frailty on clinical outcomes in patients with critical limb ischemia. *Circ Cardiovasc Interv* 2018;11:e006778.
49. Partridge JSL, Harari D, Martin FC, Peacock JL, Bell R, Mohammed A, et al. Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery. *Br J Surg* 2017;104:679-87.
50. Alvarez-Nebreda ML, Bentov N, Urman RD, Setia S, Huang JC, Pfeifer K, et al. Recommendations for preoperative management of frailty from the society for perioperative assessment and quality improvement (SPAQI). *J Clin Anesth* 2018;47:33-42.
51. Palmer J, Pymer S, Smith GE, Harwood AE, Ingle L, Huang C, et al. Presurgery exercise-based conditioning interventions (prehabilitation) in adults undergoing lower limb surgery for peripheral arterial disease. *Cochrane Database Syst Rev* 2020;9:CD013407.
52. Crowner JR, Marston WA, Freeman NLB, Sperger J, Austin HD, Steffan M, et al. The Society for Vascular Surgery Objective Performance Goals for Critical Limb Ischemia are attainable in select patients with ischemic wounds managed with wound care alone. *Ann Vasc Surg* 2022;78:28-35.
53. Setacci C. Time is tissue. *J Endovasc Ther* 2012;19:515-6.
54. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. *Eur J Vasc Endovasc Surg* 2019;58:S1-109.e33.
55. Visser L, Prent A, Banning LBD, van Leeuwen BL, Zeebregts CJ, Pol RA. Risk factors for delirium after vascular surgery: a systematic review and meta-analysis. *Ann Vasc Surg* 2021;76:500-13.
56. van Eijnsden WA, Raats JW, Mulder PG, van der Laan L. New aspects of delirium in elderly patients with critical limb ischemia. *Clin Interv Aging* 2015;10:1537-46.
57. Katznelson R, Djaiani G, Mitsakakis N, Lindsay TF, Tait G, Friedman Z, et al. Delirium following vascular surgery: increased incidence with preoperative beta-blocker administration. *Can J Anaesth* 2009;56:793-801.
58. Sasajima Y, Sasajima T, Azuma N, Akazawa K, Saito Y, Inaba M, et al. Factors related to postoperative delirium in patients with lower limb ischaemia: a prospective cohort study. *Eur J Vasc Endovasc Surg* 2012;44:411-5.
59. Visser L, Prent A, van der Laan MJ, van Leeuwen BL, Izaks GJ, Zeebregts CJ, et al. Predicting postoperative delirium after vascular surgical procedures. *J Vasc Surg* 2015;62:183-9.
60. Simoes V, Carvalho R, Duarte C, Fragata I. Postoperative delirium after vascular surgery. *Rev Port Cir Cardiorac Vasc* 2015;22:219-23.
61. Styra R, Larsen E, Dimas MA, Baston D, Elgie-Watson J, Flockhart L, et al. The effect of preoperative cognitive impairment and type of vascular surgery procedure on postoperative delirium with associated cost implications. *J Vasc Surg* 2019;69:201-9.
62. Lee DS, Lee MY, Park CM, Kim DI, Kim YW, Park YJ. Preoperative statins are associated with a reduced risk of postoperative delirium following vascular surgery. *PLoS One* 2018;13:e0192841.
63. Roijers JP, Rakke YS, Hopmans CJ, Buimer MG, de Groot HGW, Ho GH, et al. Incidence and risk factors for delirium in elderly patients with critical limb ischaemia. *Eur J Vasc Endovasc Surg* 2020;59:598-605.
64. Sasajima Y, Sasajima T, Uchida H, Kawai S, Haga M, Akasaka N, et al. Postoperative delirium in patients with chronic lower limb ischaemia: what are the specific markers? *Eur J Vasc Endovasc Surg* 2000;20:132-7.
65. Peden CJ, Miller TR, Deiner SG, Eckenhoff RC, Fleisher LA. Members of the Perioperative Brain Health Expert P. Improving perioperative brain health: an expert consensus review of key actions for the perioperative care team. *Br J Anaesth* 2021;126:423-32.
66. Grenon SM, Hiramoto J, Smolderen KG, Vittinghoff E, Whooley MA, Cohen BE. Association between depression and peripheral artery disease: insights from the heart and soul study. *J Am Heart Assoc* 2012;1:e002667.
67. Smolderen KG, Hoeks SE, Pedersen SS, van Domburg RT, de L II, Poldermans D. Lower-leg symptoms in peripheral arterial disease are associated with anxiety, depression, and anhedonia. *Vasc Med* 2009;14:297-304.

68. Brostow DP, Petrik ML, Starosta AJ, Waldo SW. Depression in patients with peripheral arterial disease: a systematic review. *Eur J Cardiovasc Nurs* 2017;16:181-93.
69. Ruo B, Liu K, Tian L, Tan J, Ferrucci L, Guralnik JM, et al. Persistent depressive symptoms and functional decline among patients with peripheral arterial disease. *Psychosom Med* 2007;69:415-24.
70. Cherr GS, Wang J, Zimmerman PM, Dosluoglu HH. Depression is associated with worse patency and recurrent leg symptoms after lower extremity revascularization. *J Vasc Surg* 2007;45:744-50.
71. Hernandez NV, Ramirez JL, Khetani SA, Spaulding KA, Gasper WJ, Hiramoto J, et al. Depression severity is associated with increased inflammation in veterans with peripheral artery disease. *Vasc Med* 2018;23:445-53.
72. Arya S, Lee S, Zahner GJ, Cohen BE, Hiramoto J, Wolkowitz OM, et al. The association of comorbid depression with mortality and amputation in veterans with peripheral artery disease. *J Vasc Surg* 2018;68:536-45.e2.
73. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. *Circulation* 2017;135:e146-603.
74. Kalbaugh CA, Loehr L, Wruck L, Lund JL, Matsushita K, Bengtson LGS, et al. Frequency of care and mortality following an incident diagnosis of peripheral artery disease in the inpatient or outpatient setting: the ARIC (atherosclerosis risk in Communities) study. *J Am Heart Assoc* 2018;7:e007332.
75. Kalbaugh CA, Gonzalez NJ, Luckett DJ, Fine J, Brothers TE, Farber MA, et al. The impact of current smoking on outcomes after infrainguinal bypass for claudication. *J Vasc Surg* 2018;68:495-502.e1.
76. Young JC, Paul NJ, Karatas TB, Kondrasov SA, McGinigle KL, Crowner JR, et al. Cigarette smoking intensity informs outcomes after open revascularization for peripheral artery disease. *J Vasc Surg* 2019;70:1973-83.e5.
77. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2014:CD000031.
78. Wong J, An D, Urman RD, Warner DO, Tonnesen H, Raveendran R, et al. Society for perioperative assessment and quality improvement (SPAQI) consensus statement on perioperative smoking cessation. *Anesth Analg* 2020;131:955-68.
79. Goodney PP, Spangler EL, Newhall K, Brooke BS, Schanzer A, Tan TW, et al. Feasibility and pilot efficacy of a brief smoking cessation intervention delivered by vascular surgeons in the Vascular Physician Offer and Report (VAPOR) Trial. *J Vasc Surg* 2017;65:1152-60.e2.
80. Newhall K, Suckow B, Spangler E, Brooke BS, Schanzer A, Tan TW, et al. Impact and duration of brief surgeon-delivered smoking cessation advice on attitudes regarding nicotine dependence and Tobacco harms for patients with peripheral arterial disease. *Ann Vasc Surg* 2017;38:113-21.
81. Wong J, Lam DP, Abrishami A, Chan MT, Chung F. Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis. *Can J Anes* 2012;59:268-79.
82. Tonnesen H, Nielsen PR, Lauritzen JB, Moller AM. Smoking and alcohol intervention before surgery: evidence for best practice. *Br J Anaesth* 2009;102:297-306.
83. Sorensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. *Ann Surg* 2012;255:1069-79.
84. Oppedal K, Møller AM, Pedersen B, Tønnesen H. Preoperative alcohol cessation prior to elective surgery. *Cochrane Database Syst Rev* 2012:CD008343.
85. Shabanzadeh DM, Sorensen LT. Alcohol consumption increases post-operative infection but not mortality: a systematic review and meta-analysis. *Surg Infect* 2015;16:657-68.
86. Verwer MC, Wijnand JGJ, Teraa M, Gremmels H, Simons JP, Conte MS, et al. External validation of the Vascular Quality Initiative prediction model for survival in no-option chronic limb-threatening ischemia patients. *J Vasc Surg* 2020;72:1659-66.e1.
87. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. *JAMA* 2007;297:1197-206.
88. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 1999;100:1043-9.
89. Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang X, Miller WJ, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. *Circulation* 2011;124:381-7.
90. Bertges DJ, Neal D, Schanzer A, Scali ST, Goodney PP, Eldrup-Jorgensen J, et al. The vascular quality initiative cardiac risk index for prediction of myocardial infarction after vascular surgery. *J Vasc Surg* 2016;64:1411-21.e4.
91. Surveillance report 2018 – Cardiovascular disease: risk assessment and reduction, including lipid modification (2014) NICE guideline CG181 [Internet]. London: National Institute for Health and Care Excellence (NICE); 2018. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK550918/>. Accessed March 22, 2023.
92. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *Circulation* 2014;130:e278-333.
93. von Meijenfeldt GCI, Rydingsward JE, van der Laan MJ, Zeebregts CJ, Christopher KB. Functional status and out-of-hospital outcomes in different types of vascular surgery patients. *Ann Vasc Surg* 2021;75:461-70.
94. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med* 2004;351:2795-804.
95. Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. *J Am Coll Cardiol* 2007;49:1763-9.
96. Garcia S, Moritz TE, Ward HB, Pierpont G, Goldman S, Larsen GC, et al. Usefulness of revascularization of patients with multivessel coronary artery disease before elective vascular surgery for abdominal aortic and peripheral occlusive disease. *Am J Cardiol* 2008;102:809-13.
97. Cooper BC. An update on contraindications for lung function testing. *Thorax* 2011;66:714-23.
98. Arozullah AM, Daley J, Henderson WC, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. *Ann Surg* 2000;232:242-53.
99. Qaseem A, Snow V, Fitterman N, Hornbake ER, Lawrence VA, Smetana GW, et al. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. *Ann Intern Med* 2006;144:575-80.
100. Latifi N, Grady D. Moving beyond guidelines-use of value-based preoperative testing. *JAMA Intern Med* 2021;181:1431-2.
101. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: national Health and Nutrition Examination Survey 1999-2002. *Diabetes Care* 2006;29:1263-8.
102. Duwayri Y, Jordan WD Jr. Diabetes, dysglycemia, and vascular surgery. *J Vasc Surg* 2020;71:701-11.
103. Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: a clinical practice guideline by the society for vascular surgery in collaboration with the American podiatric medical association and the society for vascular medicine. *J Vasc Surg* 2016;63(2 Suppl):3S-21S.
104. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. *Diabetes Care* 2001;24:1433-7.
105. Dua A, Lee CJ. Epidemiology of peripheral arterial disease and critical limb ischemia. *Tech Vasc Interv Radiol* 2016;19:91-5.
106. Biancari F, Salenius JP, Heikkinen M, Luther M, Ylonen K, Lepantalo M. Risk-scoring method for prediction of 30-day post-operative outcome after infrainguinal surgical revascularization for



- critical lower-limb ischemia: a Finnvasc registry study. *World J Surg* 2007;31:217-25; discussion 26-7.
107. Hicks CW, Najafian A, Farber A, Menard MT, Malas MB, Black JH 3rd, et al. Diabetes does not worsen outcomes following infrageniculate bypass or endovascular intervention for patients with critical limb ischemia. *J Vasc Surg* 2016;64:1667-74.e1.
  108. Melliore D, Berrahal D, Desgranges P, Allaire E, Becquemin JP, Perlemuter L, et al. Influence of diabetes on revascularisation procedures of the aorta and lower limb arteries: early results. *Eur J Vasc Endovasc Surg* 1999;17:438-41.
  109. Malmstedt J, Leander K, Wahlberg E, Karlstrom L, Alfredsson L, Swedenborg J. Outcome after leg bypass surgery for critical limb ischemia is poor in patients with diabetes: a population-based cohort study. *Diabetes Care* 2008;31:887-92.
  110. Melffle KD, Bruijnen H, Loeprrecht H, Rummenapf G, Schweiger H, Grabitz K, et al. Graft patency and clinical outcome of femorodistal arterial reconstruction in diabetic and non-diabetic patients: results of a multicentre comparative analysis. *Eur J Vasc Endovasc Surg* 2003;25:229-34.
  111. Kotagal M, Symons RC, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, et al. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. *Ann Surg* 2015;261:97-103.
  112. Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatliff C, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. *Diabetes Care* 2010;33:1783-8.
  113. Arya S, Binney ZO, Khakharia A, Long CA, Brewster LP, Wilson PW, et al. High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization. *J Vasc Surg* 2018;67:217-28.e1.
  114. McGinigle KL, Kindell DG, Strassle PD, Crouner JR, Pascarella L, Farber MA, et al. Poor glycemic control is associated with significant increase in major limb amputation and adverse events in the 30-day postoperative period after infrainguinal bypass. *J Vasc Surg* 2020;72:987-94.
  115. Pippitt K, Li M, Gurgle HE. Diabetes mellitus: screening and diagnosis. *Am Fam Physician* 2016;93:103-9.
  116. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American association of clinical endocrinologists and American College of endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015-executive summary. *Endocr Pract* 2015;21:413-37.
  117. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-59.
  118. Duggan EW, Carlson K, Umpierrez GE. Perioperative hyperglycemia management: an update. *Anesthesiology* 2017;126:547-60.
  119. Oscarsson A, Gupta A, Fredrikson M, Jarhult J, Nystrom M, Pettersson E, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. *Br J Anaesth* 2010;104:305-12.
  120. Feringa HHH, Bax JJ, Karagiannis SE, Noordzij P, van Domburg R, Klein J, et al. Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction. *Arch Gerontol Geriatr* 2009;48:116-20.
  121. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American heart association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. *Circulation* 2016;134:e123-55.
  122. Holcomb CN, Graham LA, Richman JS, Rhyne RR, Itani KM, Maddox TM, et al. The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting. *J Am Coll Cardiol* 2014;64:2730-9.
  123. Holcomb CN, Hollis RH, Graham LA, Richman JS, Valle JA, Itani KM, et al. Association of coronary stent indication with postoperative outcomes following noncardiac surgery. *JAMA Surg* 2016;151:462-9.
  124. Cruden NL, Harding SA, Flapan AD, Graham C, Wild SH, Slack R, et al. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. *Circ Cardiovasc Interv* 2010;3:236-42.
  125. Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. *JAMA* 2013;310:1462-72.
  126. Association of Anaesthetists of Great Britain and Ireland OAAaR-AUMotWPH-GW, Cook T, Gill H, Hill D, Ingram M, Makris M, Malhotra S, et al. Regional anaesthesia and patients with abnormalities of coagulation. *Anaesthesia* 2013;68:966-72.
  127. Horlocker TT, Vandermeulen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or Thrombolytic therapy: American society of regional anesthesia and pain medicine evidence-based guidelines (Fourth edition). *Reg Anesth Pain Med* 2018;43:263-309.
  128. Spahn DR, Munoz M, Klein AA, Levy JH, Zacharowski K. Patient blood management: effectiveness and future potential. *Anesthesiology* 2020;133:212-22.
  129. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. *N Engl J Med* 2020;382:1994-2004.
  130. Belch JJ, Dormandy J, Committee CW, Biasi GM, Cairls M, Diehm C, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPARE) trial. *J Vasc Surg* 2010;52:825-33. 33.e1-2.
  131. Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. *Cochrane Database Syst Rev* 2015;CD000535.
  132. Ariesen MJ, Tangelder MJ, Lawson JA, Eikelboom BC, Grobbee DE, Algra A, et al. Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) Study. *Eur J Vasc Endovasc Surg* 2005;30:154-9.
  133. Johnson WC, Williford WO. Department of Veterans Affairs Cooperative S. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. *J Vasc Surg* 2002;35:413-21.
  134. Geraghty AJ, Welch K. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. *Cochrane Database Syst Rev* 2011;CD000536.
  135. Johnson WC, Williford WO, Corson JD, Padberg FT Jr. Hemorrhagic complications during long-term postoperative warfarin administration in patients undergoing lower extremity arterial bypass surgery. *Vascular* 2004;12:362-8.
  136. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. *J Vasc Surg* 1998;28:446-57.
  137. Jackson MR, Johnson WC, Williford WO, Valentine RJ, Clagett GP. The effect of anticoagulation therapy and graft selection on the ischemic consequences of femoropopliteal bypass graft occlusion: results from a multicenter randomized clinical trial. *J Vasc Surg* 2002;35:292-8.
  138. Debus ES, Nehler MR, Govsyevev N, Bauersachs RM, Anand SS, Patel MR, et al. Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial. *Circulation* 2021;144:1104-16.
  139. Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, et al. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). *Am Heart J* 2018;199:83-91.
  140. Smith I, Kranke P, Murat I, Smith A, O'Sullivan G, Soreide E, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2011;28:556-69.



141. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American society of anesthesiologists Task Force on preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration. *Anesthesiology* 2017;126:376-93.
142. Lidder P, Thomas S, Fleming S, Hosie K, Shaw S, Lewis S. A randomized placebo controlled trial of preoperative carbohydrate drinks and early postoperative nutritional supplement drinks in colorectal surgery. *Colorectal Dis* 2013;15:737-45.
143. Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection. *Br J Surg* 2006;93:1069-76.
144. Hausel J, Nygren J, Thorell A, Lagerkranser M, Ljungqvist O. Randomized clinical trial of the effects of oral preoperative carbohydrates on postoperative nausea and vomiting after laparoscopic cholecystectomy. *Br J Surg* 2005;92:415-21.
145. Gianotti L, Biffi R, Sandini M, Marrelli D, Vignali A, Caccialanza R, et al. Preoperative oral carbohydrate load versus placebo in major elective abdominal surgery (PROCY): a randomized, placebo-controlled, multicenter, phase III trial. *Ann Surg* 2018;267:623-30.
146. Wang ZC, Wang Q, Wang WJ, Qin HL. Randomized clinical trial to compare the effects of preoperative oral carbohydrate versus placebo on insulin resistance after colorectal surgery. *Br J Surg* 2010;97:317-27.
147. Faria MS, de Aguilar-Nascimento JE, Pimenta OS, Alvarenga LC Jr, Dock-Nascimento DB, Shlessarenko N. Preoperative fasting of 2 hours minimizes insulin resistance and organic response to trauma after video-cholecystectomy: a randomized, controlled, clinical trial. *World J Surg* 2009;33:1158-64.
148. Rapp-Kesek D, Stridsberg M, Andersson LG, Berne C, Karlsson T. Insulin resistance after cardiopulmonary bypass in the elderly patient. *Scand Cardiovasc J* 2007;41:102-8.
149. Noba L, Wakefield A. Are carbohydrate drinks more effective than preoperative fasting: a systematic review of randomised controlled trials. *J Clin Nurs* 2019;28:3096-116.
150. Smith MD, McCall J, Plank L, Herbison GP, Soop M, Nygren J. Pre-operative carbohydrate treatment for enhancing recovery after elective surgery. *Cochrane Database Syst Rev* 2014;CD009161.
151. Albalawi Z, Laffin M, Gramlich L, Senior P, McAlister FA. Enhanced recovery after surgery (ERAS®) in individuals with diabetes: a systematic review. *World J Surg* 2017;41:1927-34.
152. Ge LN, Wang L, Wang F. Effectiveness and safety of preoperative oral carbohydrates in enhanced recovery after surgery protocols for patients with diabetes mellitus: a systematic review. *Biomed Res Int* 2020;2020:5623596.
153. Gould MK, Garcia DA, Wren SM, Karanickolas PJ, Arcelus JJ, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. *Chest* 2012;141(2 Suppl):e227S-77S.
154. Rabe D, Partsch H, Heidl G, Hirschl M, Kundi M, Rabe E, et al. Compression treatment in acute symptomatic proximal deep venous thrombosis - results of a worldwide survey. *Phlebology* 2021;36:526-34.
155. Rabe E, Partsch H, Morrison N, Meissner MH, Mosti G, Lattimer CR, et al. Risks and contraindications of medical compression treatment - a critical reappraisal. An international consensus statement. *Phlebology* 2020;35:447-60.
156. Ip HY, Abrishami A, Peng PW, Wong J, Chung F. Predictors of postoperative pain and analgesic consumption: a qualitative systematic review. *Anesthesiology* 2009;111:657-77.
157. By the American geriatrics society beers criteria update expert P. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 2015;63:2227-46.
158. Gaulton TG, Wunsch H, Gaskins LJ, Leonard CE, Hennessy S, Ashburn M, et al. Preoperative sedative-hypnotic medication use and adverse postoperative outcomes. *Ann Surg* 2019;274:e108-14.
159. Wongkietkachorn A, Wongkietkachorn N, Rhunsiri P. Preoperative needs-based education to reduce anxiety, increase satisfaction, and decrease time spent in day surgery: a randomized controlled trial. *World J Surg* 2018;42:666-74.
160. Itoga NK, Sceats LA, Stern JR, Mell MW. Association of opioid use and peripheral artery disease. *J Vasc Surg* 2019;70:1271-9.e1.
161. Seretny M, Colvin LA. Pain management in patients with vascular disease. *Br J Anaesth* 2016;117(Suppl 2):ii95-106.
162. Gustafsson U, Scott M, Schwenk W, Demartines N, Roulin D, Francis N, et al. Guidelines for perioperative care in elective colonic surgery: enhanced Recovery after Surgery (ERAS®) Society recommendations. *World J Surg* 2013;37:259-84.
163. Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. *Anesthesiology* 2004;101:212-27.
164. Harrison TK, Kornfeld H, Aggarwal AK, Lembke A. Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone, or Naltrexone maintenance therapy. *Anesthesiol Clin* 2018;36:345-59.
165. O'Rourke MJ, Keshock MC, Boxhorn CE, Correll DJ, O'Glasser AY, Gazelka HM, et al. Preoperative management of opioid and Non-opioid analgesics: society for perioperative assessment and quality improvement (SPAQI) consensus statement. *Mayo Clin Proc* 2021;96:1325-41.
166. Daryapeyma A, Ostlund O, Wahlgren CM. Healthcare-associated infections after lower extremity revascularization. *Eur J Vasc Endovasc Surg* 2014;48:72-7.
167. van der Slegt J, van der Laan L, Veen EJ, Hendriks Y, Romme J, Kluytmans J. Implementation of a bundle of care to reduce surgical site infections in patients undergoing vascular surgery. *PLoS One* 2013;8:e71566.
168. Hekman KE, Michel E, Blay E Jr, Helenowski IB, Hoel AW. Evidence-based bundled quality improvement intervention for reducing surgical site infection in lower extremity vascular bypass procedures. *J Am Coll Surg* 2019;228:44-53.
169. Almeida CE, Reis L, Carvalho L, Almeida CM. Costa Costa Collagen implant with gentamicin sulphate reduces surgical site infection in vascular surgery: a prospective cohort study. *Int J Surg Lond Engl* 2014;12:1100-4.
170. Turtiainen J, Saimanen EI, Makinen KT, Nykanen AI, Venermo MA, Uurto IT, et al. Effect of triclosan-coated sutures on the incidence of surgical wound infection after lower limb revascularization surgery: a randomized controlled trial. *World J Surg* 2012;36:2528-34.
171. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. *N Engl J Med* 2010;362:18-26.
172. Earnshaw JJ. Prevention of infection after vascular reconstruction. *J Antimicrob Chemother* 1989;23:480-3.
173. Fernandez-Prada M, Martinez-Ortega C, Revuelta-Marino L, Menendez-Herrero A, Navarro-Gracia JF. Evaluation of the bundle "Zero surgical site infection" to prevent surgical site infection in vascular surgery. *Ann Vasc Surg* 2017;41:160-8.
174. Tanner J, Norrie P, Melen K. Preoperative hair removal to reduce surgical site infection. *Cochrane Database Syst Rev* 2011;CD004122.
175. Leaper D, Burman-Roy S, Palanca A, Cullen K, Worster D, Gautam-Aitken E, et al. Prevention and treatment of surgical site infection: summary of NICE guidance. *BMJ* 2008;337:a1924.
176. Stewart A, Evers PS, Earnshaw JJ. Prevention of infection in arterial reconstruction. *Cochrane Database Syst Rev* 2006;CD003073.
177. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR, Society of Thoracic S. The society of Thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, Part I: duration. *Ann Thorac Surg* 2006;81:397-404.
178. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. *Emerg Infect Dis* 2001;7:828-31.
179. Bratzler DW, Houck PM. Surgical Infection Prevention Guidelines Writers W, American Academy of Orthopaedic S, American Association of Critical Care N, American Association of Nurse A, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Clin Infect Dis* 2004;38:1706-15.
180. Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA. Does intra-operative blood loss affect antibiotic serum and tissue concentrations? *Arch Surg* 1996;131:1165-71; discussion 71-2.

181. Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. *Anesth Analg* 2020;131:441-8.
182. Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. *Anesthesiology* 1999;91:693-700.
183. Koivuranta M, Laara E, Snare L, Alahuhta S. A survey of postoperative nausea and vomiting. *Anaesthesia* 1997;52:443-9.
184. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. *N Engl J Med* 2004;350:2441-51.
185. Liu SS, Strodbeck WM, Richman JM, Wu CL. A comparison of regional versus general anesthesia for ambulatory anesthesia: a meta-analysis of randomized controlled trials. *Anesth Analg* 2005;101:1634-42.
186. Apfel CC, Turan A, Souza K, Pergolizzi J, Hornuss C. Intravenous acetaminophen reduces postoperative nausea and vomiting: a systematic review and meta-analysis. *Pain* 2013;154:677-89.
187. Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. *Anesthesiology* 2005;103:1296-304.
188. Cao X, White PF, Ma H. An update on the management of postoperative nausea and vomiting. *J Anesth* 2017;31:617-26.
189. Kaye AD, Cornett EM, Chalabi J, Naim NZ, Novitch MB, Creel JB, et al. Pharmacology of antiemetics: update and current considerations in anesthesia practice. *Anesthesiol Clin* 2017;35:e41-54.
190. Lundorff L, Dich-Nielsen JO, Laugesen H, Jensen MM. Single-dose spinal anaesthesia versus incremental dosing for lower limb vascular surgery. *Acta Anaesthesiol Scand* 1999;43:405-10.
191. Thompson JPTC. Anaesthesia for lower limb revascularization. *Continuing Education Anaesth Crit Care Pain* 2005;5:89-92.
192. Traynor C, Hall GM. Endocrine and metabolic changes during surgery: anaesthetic implications. *Br J Anaesth* 1981;53:153-60.
193. Cook PT, Davies MJ, Cronin KD, Moran P. A prospective randomised trial comparing spinal anaesthesia using hyperbaric cinchocaine with general anaesthesia for lower limb vascular surgery. *Anaesth Intensive Care* 1986;14:373-80.
194. Wahba WM, Don HF, Craig DB. Post-operative epidural analgesia: effects on lung volumes. *Can Anaesth Soc J* 1975;22:519-27.
195. Baron JF, Coriat P, Mundler O, Fauchet M, Bousseau D, Viars P. Left ventricular global and regional function during lumbar epidural anesthesia in patients with and without angina pectoris. Influence of volume loading. *Anesthesiology* 1987;66:621-7.
196. Cousins MJ, Wright CJ. Graft, muscle, skin blood flow after epidural block in vascular surgical procedures. *Surg Gynecol Obstet* 1971;133:59-64.
197. Modig J, Borg T, Karlstrom G, Maripuu E, Sahlstedt B. Thromboembolism after total hip replacement: role of epidural and general anesthesia. *Anesth Analg* 1983;62:174-80.
198. Christopherson R, Beattie C, Frank SM, Norris EJ, Meinert CL, Gottlieb SO, et al. Perioperative morbidity in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. *Perioperative Ischemia Randomized Anesthesia Trial Study Group. Anesthesiology* 1993;79:422-34.
199. Bode RH, Lewis KP, Zarich SW, Pierce ET, Roberts M, Kowalchuk GJ, et al. Cardiac outcome after peripheral vascular surgery. Comparison of general and regional anesthesia. *Anesthesiology* 1996;84:3-13.
200. Rivers SP, Scher LA, Sheehan E, Veith FJ. Epidural versus general anesthesia for infrainguinal arterial reconstruction. *J Vasc Surg* 1991;14:764-8; discussion 8-70.
201. Yazigi A, Madi-Gebara S, Haddad F, Hayeck G, Tabet G. Intraoperative myocardial ischemia in peripheral vascular surgery: general anesthesia vs combined sciatic and femoral nerve blocks. *J Clin Anesth* 2005;17:499-503.
202. Hollmann MW, Rathmell JP, Lirk P. Optimal postoperative pain management: redefining the role for opioids. *Lancet* 2019;393:1483-5.
203. Myles PS, Bellomo R, Corcoran T, Forbes A, Peyton P, Story D, et al. Restrictive versus liberal fluid therapy for major abdominal surgery. *N Engl J Med* 2018;378:2263-74.
204. Hasanin A, Mourad KH, Farouk I, Refaat S, Nabih A, Raouf SA, et al. The impact of goal-directed fluid therapy in prolonged major abdominal surgery on extravascular lung Water and oxygenation: a randomized controlled trial. *Open Access Maced J Med Sci* 2019;7:1276-81.
205. Resalt-Pereira M, Munoz JL, Miranda E, Cuquerella V, Perez A. Goal-directed fluid therapy on laparoscopic colorectal surgery within enhanced recovery after surgery program. Efecto de la fluidoterapia guiada por objetivos en cirugía colorrectal laparoscópica dentro de un protocolo de rehabilitación multimodal. *Rev Esp Anestesiol Reanim* 2019;66:259-66.
206. Feng S, Yang S, Xiao W, Wang X, Yang K, Wang T. Effects of perioperative goal-directed fluid therapy combined with the application of alpha-1 adrenergic agonists on postoperative outcomes: a systematic review and meta-analysis. *BMC Anesthesiol* 2018;18:113.
207. Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. *Br J Anaesth* 2018;121:706-21.
208. van Waes JA, van Klei WA, Wijjesundera DN, van Wolfswinkel L, Lindsay TF, Beattie WS. Association between intraoperative hypotension and myocardial injury after vascular surgery. *Anesthesiology* 2016;124:35-44.
209. Hypothermia: prevention and management in adults having surgery. London: National Institute for Health and Care Excellence (NICE); 2016. (NICE Clinical Guidelines, No. 65). Available at: <https://www.ncbi.nlm.nih.gov/books/NBK554181/>. Accessed March 22, 2023.
210. Shantikumar S, Patel S, Handa A. The role of cell salvage autotransfusion in abdominal aortic aneurysm surgery. *Eur J Vasc Endovasc Surg* 2011;42:577-84.
211. Takagi H, Sekino S, Kato T, Matsuno Y, Umemoto T. Intraoperative autotransfusion in abdominal aortic aneurysm surgery: meta-analysis of randomized controlled trials. *Arch Surg* 2007;142:1098-101.
212. Klein AA, Bailey CR, Charlton AJ, Evans E, Guckian-Fisher M, McCrossan R, et al. Association of Anaesthetists guidelines: cell salvage for peri-operative blood conservation 2018. *Anaesthesia* 2018;73:1141-50.
213. Goodnough LT, Monk TG, Sicard G, Satterfield SA, Allen B, Anderson CB, et al. Intraoperative salvage in patients undergoing elective abdominal aortic aneurysm repair: an analysis of cost and benefit. *J Vasc Surg* 1996;24:213-8.
214. van de Weijer MA, Kruse RR, Schamp K, Zeebregts CJ, Reijnen MM. Morbidity of femoropopliteal bypass surgery. *Semin Vasc Surg* 2015;28:112-21.
215. Kuy S, Dua A, Desai S, Dua A, Patel B, Tondravi N, et al. Surgical site infections after lower extremity revascularization procedures involving groin incisions. *Ann Vasc Surg* 2014;28:53-8.
216. Canteras M, Baptista-Silva JC, do Carmo Novaes F, Cacione DG. Transverse versus vertical groin incision for femoral artery approach. *Cochrane Database Syst Rev* 2020;4:CD013153.
217. Ng JJ, Tan JKH, Lee JWK, Choong A. Longitudinal versus transverse incision for common femoral artery exposure: a systematic review and meta-analysis. *ANZ J Surg* 2021;91:822-31.
218. Sway A, Solomkin JS, Pittet D, Kilpatrick C. Methodology and background for the World health organization global guidelines on the prevention of surgical site infection. *Surg Infect (Larchmt)* 2018;19:33-9.
219. Gwilym BL, Dovell G, Dattani N, Ambler GK, Shalhoub J, Forsythe RO, et al. Editor's choice - systematic review and meta-analysis of wound adjuncts for the prevention of groin wound surgical site infection in arterial surgery. *Eur J Vasc Endovasc Surg* 2021;61:636-46.
220. Kwon J, Staley C, McCullough M, Goss S, Arosemena M, Abai B, et al. A randomized clinical trial evaluating negative pressure therapy to decrease vascular groin incision complications. *J Vasc Surg* 2018;68:1744-52.
221. Matatov T, Reddy KN, Doucet LD, Zhao CX, Zhang WW. Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. *J Vasc Surg* 2013;57:791-5.
222. Lee K, Murphy PB, Ingves MV, Duncan A, DeRose G, Dubois L, et al. Randomized clinical trial of negative pressure wound therapy for high-risk groin wounds in lower extremity revascularization. *J Vasc Surg* 2017;66:1814-9.

223. Bua N, Smith GE, Totty JP, Pan D, Wallace T, Carradice D, et al. Dialkylcarbamoyl Chloride dressings in the prevention of surgical site infections after Nonimplant vascular surgery. *Ann Vasc Surg* 2017;44:387-92.
224. Healy D, Clarke-Moloney M, Hannigan A, Walsh S. Wound drainage for lower limb arterial surgery. *Cochrane Database Syst Rev* 2016;11:CD011111.
225. Bennett KM, Levinson H, Scarborough JE, Shortell CK. Validated prediction model for severe groin wound infection after lower extremity revascularization procedures. *J Vasc Surg* 2016;63:414-9.
226. Wallace AB, Piper ML, Holland M, Lee S, Orringer M, Eichler C, et al. Prophylactic muscle flaps in primary vascular procedures of the groin. *Ann Vasc Surg* 2022;78:77-83.
227. Teixeira PC, Woo K, Weaver FA, Rowe VL. Vein harvesting technique for infrainguinal arterial bypass with great saphenous vein and its association with surgical site infection and graft patency. *J Vasc Surg* 2015;61:1264-71.e2.
228. Santo VJ, Dargon PT, Azarbal AF, Liem TK, Mitchell EL, Moneta GL, et al. Open versus endoscopic great saphenous vein harvest for lower extremity revascularization of critical limb ischemia. *J Vasc Surg* 2014;59:427-34.
229. Peinado Cebrian J, Flores Herrero A, Salgado Lopetegui CL, Lamarca Mendoza MP, Montoya Ching R, Seco SE, et al. Comparison of bypass with endoscopically harvested internal saphenous vein versus bypass with surgically harvested internal saphenous vein for lower limb arterial disease. *Ann Vasc Surg* 2015;29:1353-62.
230. Fereydooni A, Zhou B, Xu Y, Deng Y, Dardik A, Ochoa Chaar CI. Rapid increase in hybrid surgery for the treatment of peripheral artery disease in the Vascular Quality Initiative database. *J Vasc Surg* 2020;72:977-86.e1.
231. DeCarlo C, Boitano LT, Sumpio B, Latz CA, Feldman Z, Pendleton AA, et al. Comparative analysis of outcomes in patients undergoing femoral endarterectomy plus endovascular (hybrid) or bypass for femoropopliteal occlusive disease. *Ann Vasc Surg* 2021;72:227-36.
232. Jorshery SD, Skrip L, Sarac T, Ochoa Chaar CI. Hybrid femoropopliteal procedures are associated with improved perioperative outcomes compared with bypass. *J Vasc Surg* 2018;68:1447-54.e5.
233. Elbadawy A, Ali H, Saleh M. Midterm outcomes of common femoral endarterectomy combined with inflow and outflow endovascular treatment for chronic limb threatening ischaemia. *Eur J Vasc Endovasc Surg* 2020;59:947-55.
234. Neseek-Adam V, Rasić Z, Schwarz D, Grizelj-Stojčić E, Rasić D, Krstonjević Z, et al. The effect of spinal versus general anesthesia on postoperative pain and analgesic requirements in patients undergoing peripheral vascular surgery. *Coll Antropol* 2012;36:1301-5.
235. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the American pain society, the American society of regional anesthesia and pain medicine, and the American society of anesthesiologists' Committee on regional anesthesia, executive Committee, and administrative Council. *J Pain* 2016;17:131-57.
236. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. *Cochrane Database Syst Rev* 2006;CD004603.
237. Blaudszun G, Lysakowski C, Elia N, Tramer MR. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. *Anesthesiology* 2012;116:1312-22.
238. Howard R, Albright J, Englesbe M, Osborne N, Henke P. Opioid use in patients with peripheral arterial disease undergoing lower extremity bypass. *J Vasc Surg* 2022;75:998-1007.
239. Velazquez-Ramirez G, Krebs J, Stafford JM, Ur R, Craven TE, Stutsrim AE, et al. Prevalence of chronic opioid use in patients with peripheral arterial disease undergoing revascularization. *J Vasc Surg* 2022;75:186-94.
240. Long CA, Fang ZB, Hu FY, Arya S, Brewster LP, Duggan E, et al. Poor glycemic control is a strong predictor of postoperative morbidity and mortality in patients undergoing vascular surgery. *J Vasc Surg* 2019;69:1219-26.
241. Conte MS, Pomposelli FB. Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction. *J Vasc Surg* 2015;61(3 Suppl):1S.
242. American Diabetes Association Professional Practice C, American Diabetes Association Professional Practice C, Draznin B, Aroda VR, Bakris G, Benson G, et al. 16. Diabetes care in the hospital: standards of medical care in diabetes-2022. *Diabetes Care* 2022;45(Supplement 1):S244-53.
243. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2012;97:16-38.
244. Subramaniam B, Panzica PJ, Novack V, Mahmood F, Matyal R, Mitchell JD, et al. Continuous perioperative insulin infusion decreases major cardiovascular events in patients undergoing vascular surgery: a prospective, randomized trial. *Anesthesiology* 2009;110:970-7.
245. Investigators N-SS, Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, et al. Hypoglycemia and risk of death in critically ill patients. *N Engl J Med* 2012;367:1108-18.
246. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA, Healthcare Infection Control Practices Advisory C, et al. Guideline for prevention of catheter-associated urinary tract infections 2009. *Infect Control Hosp Epidemiol* 2010;31:319-26.
247. Zil EAA, Patel K, Goldfarb M, Aziz F. Postoperative decline in the ambulatory function after lower extremity bypass is associated with higher short and long-term mortality. *J Vasc Surg* 2022;5:2002-12.
248. Arias-Fernandez P, Romero-Martin M, Gomez-Salgado J, Fernandez-Garcia D. Rehabilitation and early mobilization in the critical patient: systematic review. *J Phys Ther Sci* 2018;30:1193-201.
249. Schallom M, Tymkew H, Vyders K, Prentice D, Sona C, Norris T, et al. Implementation of an interdisciplinary AACN early mobility protocol. *Crit Care Nurse* 2020;40:e7-17.
250. Causey MW, Ahmed A, Wu B, Gasper WJ, Reyzelman A, Vartanian SM, et al. Society for Vascular Surgery limb stage and patient risk correlate with outcomes in an amputation prevention program. *J Vasc Surg* 2016;63:1563-73.e2.
251. Flores AM, Mell MW, Dalman RL, Chandra V. Benefit of multidisciplinary wound care center on the volume and outcomes of a vascular surgery practice. *J Vasc Surg* 2019;70:1612-9.
252. Tahhan G, Farber A, Shah NK, Krafchik BM, Sachs TE, Kalish JA, et al. Characterization of planned and unplanned 30-day readmissions following vascular surgical procedures. *Vasc Endovascular Surg* 2017;51:17-22.
253. Knighton A, Martin G, Sounderajah V, Warren L, Markiewicz O, Riga C, et al. Avoidable 30-day readmissions in patients undergoing vascular surgery. *BJS Open* 2019;3:759-66.
254. Eun JC, Nehler MR, Black JH 3rd, Glebova NO. Measures to reduce unplanned readmissions after vascular surgery. *Semin Vasc Surg* 2015;28:103-11.
255. Johnson A, Sandford J, Tyndall J. Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home. *Cochrane Database Syst Rev* 2003;CD003716.
256. Li LT, Mills WL, Gutierrez AM, Herman LI, Berger DH, Naik AD. A patient-centered early warning system to prevent readmission after colorectal surgery: a national consensus using the Delphi method. *J Am Coll Surg* 2013;216:210-6.e6.
257. Mistiaen P, Poot E. Telephone follow-up, initiated by a hospital-based health professional, for postdischarge problems in patients discharged from hospital to home. *Cochrane Database Syst Rev* 2006;4:CD004510.

Submitted Dec 5, 2022; accepted Jan 3, 2023.